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The so-called bacterial “superbugs” are largely resistant to some of the most 
commonly prescribed antibiotics, including a drug class known as cephalosporins 
used to treat many hospital and community-acquired infections. This major public 
health threat has been acknowledged for decades by the Centers for Disease Control 
(CDC) as a major concern; yet, the detection of superbugs has not been made routine 
since standard testing practices have been limited to specialized “central” laboratories 
with sophisticated yet bulky and expensive equipment and highly trained personnel. 
As a result, the lack of simpler testing methods that can be used in everyday clinics 
and doctor’s offices can be viewed as a source of error contributing to incorrect 
antibiotic treatment and poorer patient outcomes, factors that drive even more 
advanced resistance, depleting our drugs or last resort.  
 
 
In this dissertation, we explore new strategies for simplified methods to test 
for cephalosporin resistance in order to give higher accessibility in the timely 
detection of superbugs to support the improvement of patient care. To do this, we take 
an organic chemistry and biochemical approach to develop new detection molecules 
that report resistance activity in bacteria expressing extended-spectrum β-lactamase 
(ESBL) enzymes, one of the most prolific resistance strategies used by superbugs. 
Next, we describe methods of integrating these detection molecules into practical 
testing methods, and detail the engineering of simpler assays that allow for rapid 
readout of ESBL phenotypes using commonplace laboratory plate readers, portable 
Raman devices, and even handheld personal glucose meters (used for diabetes 
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Chapter 1: Introduction 
1.1 Overview 
Antimicrobial resistance (AMR) to β-lactam compounds poses a critical and 
mounting challenge in the treatment of community and hospital acquired infections. 
The Centers for Disease Control and Prevention (CDC) listed extended-spectrum β-
lactamase (ESBL) producing Enterobacteriaceae as one of the biggest threats in its 
2013 Antimicrobial Resistance Threats Report.1,2 Though enumerated under “serious 
threats,” ESBL pathogens are a direct evolutionary forerunner of carbapenem-
resistant Enterobacteriaceae, declared as an “urgent threat” to public health. The 
etiology of resistant cases lies largely in Gram negative Enterobacteriaceae which 
produce and disseminate plasmid-encoded enzymes capable of hydrolyzing β-lactam 
antibiotics which range from older (-cillins) to more advanced (cephalosporins, 
carbapenems). Incorrect antibiotic treatment not only leads to poor patient outcomes, 
but also places selective pressure on the pathogen, driving AMR advancement. 
Therefore, timely and accurate testing is crucial for good patient outcomes and for 
safeguarding public health.  
 
As recommended by the Clinical and Laboratory Standards Institute (CLSI), the 
current standard in antimicrobial susceptibility testing (AST) relies on bacterial 
culture (disk diffusion susceptibility test, Etest, broth dilution).3 Results require days-
long turnaround; in cases of sepsis, this timeline can prove to be too long, giving the 




antibiotic stewardship recommended guidelines.4 The need for faster reporting has led 
to the adoption of four US FDA-approved automated systems that can produce 
susceptibility results in the range of 3.5 hours to overnight: MicroScan WalkAway 
(Siemens Healthcare Diagnostics), BD Phoenix Automated Microbiology System 
(BD Diagnostics), Vitek 2 System (bioMérieux), and Sensititre ARIS 2X (Trek 
Diagnostic Systems).5 These high-throughput systems measure minimum inhibitory 
concentration (MIC) either by colorimetric, turbidimetric, or fluorometric means, 
with a variable time-to-result for each readout method depending on the pathogen. In 
the case of the MicroScan WalkAway, fluorogenic substrates are used to test Gram 
negative susceptibility, and have a generally faster turnaround time (3.5-7 hours) than 
turbidimetric end-point measurement for general AMR pathogens (4.5-18 hours). 
Genotypic tests (ESBL Array, Check-Points) may also provide resistance 
confirmation, but require more involved sample preparation than simple broth 
inoculation, and are typically reserved for cases with discrepant phenotypic test 
results. Furthermore, as genotypic methods are designed to detect single nucleotide 
polymorphisms (SNPs), the established testing repertoire has been limited to the TEM 
and SHV families of ESBLs, and only include a small handful of CTX-M variants.6 
Though TEM and SHV evolutionary expansion via SNPs represents a large portion of 
enzyme mutations that are conducive to resistance,7 sequencing efforts are far from 
fully encompassing the widening scope of this rapidly evolving gene. 
 
Rapid phenotypic tests including acidimetric and iodometric methods exist as 




readouts. The acidimetric test relies on the generation of a carboxylic acid from the 
hydrolyzed β-lactam, which acidifies unbuffered systems, and methodologies to 
measure the resultant pH change have been reported in the literature using aqueous 
phenol red in a tube format or bromocresol purple in the form of strips.8 The 
iodometric test is limited to the detection of penicillinase activity, as it relies on the 
production of penicilloic acid to reduce iodine which changes color when in complex 
with starch.9 Though rapid, there exists a critical tradeoff: these tests are susceptible 
to producing false positives as reduction of iodine and solution acidification are 
highly subject to variabilities in sample and environment, often causing them to occur 
nonspecifically;10 furthermore, the β-lactamase enzymes detected by these methods 
do not encompass the broad- or extended-spectrum genetic permutations whose 
ascertainment is currently of crucial clinical and public health consequence.10 
 
As more refined specificity is required to categorically identify a pathogen as ESBL-
positive and differentiate from penicillinase-only producers, several β-lactam derived 
chromogenic compounds (Nitrocefin, pyridine‐2‐azo‐p‐dimethylaniline cephalosporin 
(PADAC), CENTA) have previously been described as “reporters” or “sensors” of 
the resistance phenotype, to better serve as effective detection substrates in the study 
of ESBL activity.11,12 Nitrocefin has been established as a clinical laboratory test, and 
is rapidly hydrolyzed by a range of β-lactamases upon incubation with bacterial 
isolates from overnight culture. Single colonies are placed in a tube containing a 
buffered solution of Nitrocefin, or dropped onto paper disks impregnated with the 




Diagnostics). Uncleaved Nitrocefin is visually observable as a yellow color and has 
an optical absorbance peak at 390 nm, a spectral property that would preliminarily 
indicate a β-lactamase-negative sample due to the apparent lack of enzymatic activity. 
In the presence of β-lactamase capable of cleaving early-generation cephalosporins, 
the amide bond of the β-lactam ring in Nitrocefin is hydrolyzed, producing an 
observable red color change and optical absorbance peak shift to 486 nm from 389 
nm at neutral pH, which can be measured spectrophotometrically using a sufficiently 
sensitive absorbance reader to quantify a given β-lactamase-positive sample. Since 
single colonies positive for β-lactamase would generally produce copious amounts of 
the enzyme, especially if grown in selective media containing inducing factors, the 
absorbance shift can be expected to be visually observable without instrumentation as 
a yellow to red color change within 5 minutes. In recommended protocols, access of 
the detection substrate to β-lactamase is further enhanced by CFU concentration via 
centrifugation, and by cell wall disruption via sonication.13 However, Nitrocefin and 
CENTA are generally cleavable by most β-lactamases, and therefore do not 
distinguish a given isolate explicitly as an ESBL producer. 
 
Commercially available resistance testing agar plates containing multiple 
chromogenic substrates (chromID ESBL, CHROMagar ESBL, bioMérieux; 
Brilliance ESBL, Oxoid) can provide a convenient format for culling more specific 
resistance information.14 Single colonies from a pre-cultured sample are streaked onto 
the plates and incubated overnight; specific color change in each colony occurs 




bacterial growth and metabolism. This can provide identifying information by 
narrowing down to groups of putative bacterial species based on the enzyme producer 
profile (e.g., earlier generation β-lactamases producers, gluconuridase producers, 
galactosidase producers). More specific ESBL determination can be performed in 
plates additionally supplemented with specific cephalosporin antibiotics (e.g., 
cefpodoxime, cefepime) in addition to Nitrocefin. Though these methods can 
determine specific resistance information, each with their own set of advantages, they 
all require extended culture times.  
 
As fluorescence measurement is generally accepted to have higher sensitivities than 
chromogens, which rely on absorbance spectrophotometry, the development of 
fluorogenic ESBL substrates has expanded the phenotypic detection repertoire with 
the promise of lower limits of detection.15–20 They include substrates that have been 
designed to release well-characterized coumarins upon specific cleavage by advanced 
ESBLs including metallo-β-lactamases (MBLs), an improvement on substrates unable 
to distinguish β-lactamases with extended-spectrum profiles from narrow-spectrum.21 
 
Yet, as previously described methodologies require the specialization of a central 
microbiology lab facility, resistance testing away from equipped central labs, such as 
in disadvantaged regions, remains an underserved goal. Electrochemical readouts of a 
redox-active reporter have the potential to meet this paradigm, as demonstrated by the 
handheld personal glucose meter (PGM). Recently the PGM has been re-envisioned 




blood glucose biomarkers.22,23 Biomedical research groups have engineered schemes 
incorporating a variety of materials into pathways to ultimately produce glucose for 
endpoint quantitation; this has been described for DNA aptamer-based HIV 
diagnostics as well as detection of contaminants such as melamine in milk.24,25 
Amperometric measurements of hydrolyzed Nitrocefin have also been reported in the 
literature, with the aim toward rapid detection of ESBL activity using disposable 
screen-printed sensors with small sample volumes to enable robust, field-portable 
instrumentation.26 
 
1.2 Public health implications 
Numerous public health organizations such as the Centers for Disease Control and 
Prevention (CDC), World Health Organization (WHO), Infectious Diseases Society 
of America (IDSA) have declared the rapid emergence of resistant bacteria to be a 
major “crisis”, describing the situation in such dire terms as a “nightmare scenario” 
that has potentially “catastrophic consequences”. As we are now in a “post-antibiotic 
era” as declared by the CDC in 2013, several other agencies including the Institute of 
Medicine and federal Interagency Task Force on Antimicrobial Resistance have 
evaluated that multidrug resistance is an impending threat to both public health and 
national security for the United States. The antibiotic pipeline has in essence “dried 
up” since the 1980s, starving the medical field of new resources to continually battle 
the rising threat of multidrug resistance. Having decreased steadily over last 3 
decades, with 30 new antibiotics developed between the years of 1980-1989 dropping 




the low economic appeal that fails to yield worthwhile returns for many large 
companies in the pharmaceutical industry. Other discouraging factors include the 
larger challenges posed by the smaller market of Gram negative pathogens, as they 
more rapidly acquire resistance phenotypes and are therefore more unpredictable (in 
contrast with more widespread and slowly evolving Gram positive methicillin-
resistant Staphylococcus aureus). These considerations paired with regulatory 
approval barriers prove to be a major disincentivizing obstacle to even more 
optimistic companies. 
 
Maintenance of proper antimicrobial stewardship through judicious use of our 
remaining antibiotics serves as one of the most implementable strategies available. 
Overuse or inappropriate prescribing of antibiotics is currently the main driver in the 
evolution of resistance: incorrect treatment occurs in 30-50% of cases (either by 
choice of agent or duration of therapy),4 and up to 60% of antibiotics prescribed in 
intensive care units have been determined to be unnecessary, inappropriate, or 
suboptimal.5 Subtherapeutic or subinhibitory administration promotes evolution of 
resistance genes by way of mutagenesis, horizontal gene transfer (HGT), or altered 
gene expression, leading to bacterial strain diversification. 
1.3 Management efforts and stewardship 
Currently, management strategies for the ongoing antibiotic resistance crisis have 
been generally two-fold: revitalization of antimicrobial drug discovery programs by 
the pharmaceuticals industry, and implementation of public initiatives through 




Infectious Diseases Society of America28 (10x’20 Initiative). Though new drugs have 
reached advanced stages in the development pipeline, general consensus maintains 
emphasis on antibiotic stewardship programs that mandate behavioral practices for 
control and reduction of resistant pathogens: surveillance, infection control, and 
selection of optimal therapeutic combinations and dosing regimens. The rapid 
detection of ESBL at the point-of-care can strengthen antimicrobial stewardship not 
only by aiding in treatment measures in the case of susceptible pathogen detection, 
but also contribute surveillance data for Antibiogram-assisted resistance incidence 
tracking and monitoring.29 The CDC has published guidelines to be taken every time 
antibiotics are prescribed:30 
 
1) Order recommended cultures before antibiotics are given and start drugs 
promptly. 
2) Make sure indication, dose, and expected duration are specified in the 
patient record. 
3) Reassess within 48 hours and adjust Rx if necessary or stop Rx if indicated. 
 
Results from culture-based follow-up testing can later confirm initial rapid-test 
readouts, as well as determine MIC; however, there are yet two considerations: 
standard clinical practices typically recommend administering the highest effective 
dose that is still physiologically safe for the patient, rendering MIC determinations 




able to predict resistance/ susceptibility patterns in the patient, posing an added 
challenge.31  
 
Ultimate goals of this work. The assay methodologies described in the current work 
can be conceived as future ex vivo clinical tests as they aims to directly interrogate 
bacteria within patient samples. Further, in addition to directly impacting patient 
health outcomes and contributing to public health assessment in positive ways, the 
present work aims to bring rapid antibiotic resistance testing out of highly specialized 
central laboratories and into standard laboratories found in hospitals, clinics, and 
doctor’s offices. Ultimately, the work aims to bring rapid resistance testing to any 
low-resource setting such as underserved communities or even geographically 
isolated regions without complete access to healthcare facilities, through 
compatibility engineering of our assays for the implementation of portable equipment 






Chapter 2: Background 
2.1 Βeta-lactam antibiotics 
2.1.1 Brief history of Cephalosporins 
Once considered a medical blessing, the first β-lactam antibiotics eventually fell to 
newly emerging strains of resistance-harboring bacteria. Newer generation β-lactams 
known as cephalosporins were developed to have broad-spectrum bactericidal 
properties while also having lower toxicity and allergenicity. However, the 
conundrum to their popularity also lay in their broad targeting scope: these antibiotics 
had differential efficacies against bacteria, exerting evolutionary pressure that 
selected for resistant organisms and drove their overgrowth and diversification. 
Among common pathogens that have been selected, some constitutively possess a 
lower degree of resistance to cephalosporins, but may develop into more broadly 
resistant mutants that are capable of secondary transfer into other species. One such 
example is Pseudomonas aeruginosa, whose enhanced resistance commonly arises 
from treatment with oral cephalosporins (namely ceftriaxone or ceftazidime) 
prescribed for urinary tract infection, and can transfer plasmid-encoded ESBL 
capacity into Enterobacteriaceae.32 
 
Overgrowth, or increased population densities of potentially pathogenic bacteria, 
occurring in multiply resistant strains can be especially troublesome in the hospital 
environment.31 The majority of patients and healthy individuals given cephalosporins 
develop enterococcal overgrowth in the gastrointestinal tract due to the drug’s 




microbiome—caused more often by cephalosporins than other antibiotic types—can 
result in associated diarrhea and colitis, clinical diseases often attributed to 
Clostridium difficile overgrowth. Though treatment options include vancomycin, 
metronidazole, or a combination of both, a high frequency of treatment failures has 
been documented.31 As a result, C. difficile has gained widespread notoriety due to 
costly and debilitating hospital outbreaks, with incidences on the rise in the UK over 
the last decade. As the association of cephalosporins and C. difficile has been well 
established, treatment restrictions put in place in clinical practice have already 
reduced the incidence of C. difficile cases among the elderly.33,34 This modified 
practice strategy has proven successful in reducing deleterious repercussions of 
cephalosporin use, epitomizing improved clinical stewardship. We therefore posit that 
a more informed practice enabled by a timely resistance test can further improve the 
resolution of treatment on a case-by-case basis, zeroing in on instances that 
necessitate last resort administration. 
 
2.1.2 Mode of action 
The β-lactam class of antibiotics exert their antibacterial effects through the inhibition 
of bacterial cell wall synthesis.35 They interrupt the transpeptidation process that links 
individual peptidoglycan components of the cell wall together. The bacterial cell wall 
is a highly complex, rigid structure whose main building block is peptidoglycan, a 
molecule composed of sugars and amino acids. Chains of peptidoglycan are cross-
linked to form tight, mesh-like networks outside the plasma membrane and serve to 




sugar-based glycan component consists of chains of alternating N-acetylmuramic acid 
(NAM), to which a short, three- to five- amino acid chain is attached, and N-
acetylglucosamine (NAG).36 Crosslinking occurs between these short peptides in 
adjacent glycan chains to yield the structural lattice that forms the cell wall. 
Specialized bacterial enzymes known as penicillin binding proteins (PBPs) are 
essential transpeptidases that catalyze the crosslinking reaction by recognizing the D-
Ala-D-Ala motif of the short peptides attached to NAM. As β-lactams have high 
steric similarity to the D-Ala-D-Ala motif, they can act as a substrate due to their 
resultant high affinity to PBPs.37 Upon binding to PBPs, β-lactams exert their 
antibiotic action acylating the PBPs to form an irreversible covalent bond, thereby 
inactivating their cross-linking ability and arresting cell wall synthesis. Meanwhile, 
autolytic restructuring enzymes present in bacteria continue to degrade the cell wall, 




results in cell lysis.38,39
 
Figure 2.1. Schematic of beta-lactamase activity against beta-lactam antibiotics that inhibit Gram 
negative bacterial cell wall synthesis. Image from The Chen Lab © 2019, Univ. of South Florida. Used 
with permission. 
 
2.1.3 Classes of β-lactams 
Penicillins. In the penicillins (Fig. 2.2), the β-lactam ring is fused to a five-membered 
thiazolidine ring. Newer penicillins have been formulated through modifications of 
the acyl side chain attached to the C6 carbon (R
1). Most examples of this give rise to 
ampicillin derivatives such as carbenicillin (carboxy group in place of amino group), 
ticarcillin (substitution of phenyl group for thiophene in addition to carboxy group in 
place of amino group), and other iterations of acyl side chain modification (ureido 




substitutions in carbenicillin and ticarcillin decrease binding to PBPs of S. faecalis, 
and therefore are less effective against the pathogen; however antibiotics of the latter 
modifications have greater binding affinities to PBPs as well as increased penetration 
into the cell walls of Gram negative rods including Pseudomonas aeruginosa thereby 
giving them greater effectiveness overall. 
 
Cephalosporins. Cephalosporins (Fig. 2.2) have a β-lactam ring fused to a six-
membered dihydrothiazine ring. The cephalosporin nucleus is inherently more 
resistant to β-lactamase hydrolysis than that of penicillins, making it the next iteration 
in the advancement of the β-lactam antibiotics after the spread of penicillin resistance, 
especially among Staphylococcus aureus and E. coli. There is also greater drug 
development potential in the cephalosporins because of a greater number of 
therapeutically important modification sites: the 1-position sulfur, 7-position carbon 
directly or via its acyl group, and the 3-position carbon.41–45 
 
Carbapenems. This class of β-lactam antibiotics is marked by its resistance to 
hydrolytic inactivation by β-lactamases, and maintain their inhibitory mode of action 
by reacting with the active-site serine residue to form a long-lived acyl-enzyme 
intermediate.46,47 The structure of carbapenems (Fig. 2.2) consists of a β-lactam ring 
fused to a penicillin-like five-membered ring that has a carbon replacing the sulfur at 
C-1, and also possesses a double bond between C-2 and C-3. Their small size allows 
greater penetrability through Gram negative bacterial cell walls. A hydroxyethyl side 




cephalosporins—has given the carbapenems marked resistance to β-lactamase 
hydrolysis, as in the case of imipenem. Yet, recent evolution of β-lactamase-mediated 
resistance driven in the past 1-2 decades by poor antibiotic stewardship has resulted 
in the rise of class A carbapenemases and class B metallo-β-lactamases.46,47 (This will 
be detailed in the next section under “metallo-β-lactamases”.) 
 
Monobactams. These are a group of novel compounds related to the β-lactams that 
only have a single ring structure as opposed to the bicyclic structure characteristic of 
the other β-lactams (Fig 2.2). As with the previous β-lactams, the monobactams can 
be similarly modified to diversify the therapeutic portfolio. The 1-sulfonic acid 
facilitates binding interactions with PBPs by lowering the activation energy, as in 
aztreonam.48  
 
Inhibitors. β-lactamase inhibitors come in two types: clavulanic acid and sulbactam. 
These compounds structurally resemble the penicillins (Fig. 2.2) and while not 
effective by themselves as an antibiotic, when administered in combination 
formulations, help to enhance in vitro activity for diagnostic purposes as they exert 
protective effects over certain β-lactam antibiotics. Their inhibitory activity is 
sometimes described as “suicide-like” as they are designed to preferentially bind to β-










2.1.4 Clinical use 
Clinical uses - penicillins. Extended-spectrum penicillins are used for P. aeruginosa 
and other aerobic Gram negative rods and anaerobes, with high response rates (60-
80%) in bacteremias, intraabdominal infections, female genitourinary tract infections, 
bone and soft tissue infections, and pneumonias.55–71 Notably, no differences in 
efficacy are observed in comparative trials with extended-spectrum penicillins. 
However, monotherapeutic treatment has been associated with colonization by 
resistant organisms in 6 to 39 percent of cases;66,67 superinfection in 7-12 percent of 
cases; failures to eliminate organisms despite patient clinical improvement in 25-50 
percent of cases.63,70–72 Therefore, as single-agent treatment yields poor response in 
compromised hosts, they have been recommended for use in combination with 
aminoglycosides especially for serious infections. Combination therapy has marked 
improvements in patient response rates, improving efficacy in a variety of clinical 
situations: 56-97 percent response rates in compromised hosts (e.g., patients with 
neutropenia), 30-60 percent of hosts harboring P. aeruginosa (e.g., bacteremia, 
endocarditis, osteomyelitis, malignant otitis externa, keratitis, central nervous system 
infection), 20-50 percent of hosts harboring Enterobacteriaceae infection.71 For 
anaerobe colonization of intraabdominal or pelvic spaces, or mixed aerobic-anaerobic 
infections of the lung, extended-spectrum penicillins have produced response rates of 
70-90 percent.73–75 Monotherapy is associated with recurrence in up to 20% of 
patients; combination therapy is therefore recommended for its high efficacy. Though 




inflammatory, and biliary surgery, first-generation cephalosporins are equally 
effective and less expensive.72–78 
 
Clavulanic acid with ticarcillin (Timentin, 3 g ticarcillin and 100 mg clavulanic acid, 
intravenous administration) improves ticarcillin’s efficacy against ticarcillin-resistant 
strains of Enterobacteriaceae, H. influenzae, S. aureus, and bacteroides by 60-80 
percent; however, no increased activity is reported in P. aeruginosa. Clavulanic acid 
and amoxicillin (Augmentin, 250-500 mg amoxicillin and 125 mg clavulanic acid, 
oral preparation) provides enhanced activity against β-lactamase producers of 
Staphylococcus, Branhamella catarrhalis, H. influenzae, Neisseria gonorrhoeae, and 
bacteroides.40 
 
Clinical uses – cephalosporins & carbapenems: Treatment and outcome of infection 
by ESBL producers. The efficacy of penicillins and its related compounds flounders 
in the face of β-lactamase enzymes with mutuations rendering them capable of 
inactivating these older-generation antibiotics.79–82 Therefore, the range of therapeutic 
options is reduced when facing infections by ESBL-producing organisms able to 
hydrolyze many β-lactam antibiotics. Plasmids that these organisms harbor often 
carry genes that also encode for resistance to aminoglycosides and other antimicrobial 
agents such as trimethioprim and sulfamethoxazole; plasmid-encoded resistance to 
cephalosporins is also associated with susceptibility decrease to quinolones including 
ciprofloxacin.83–86 Interestingly, in Klebsiella pneumoniae clinical isolates, porin loss 




expressing active quinolone efflux activity. Β-lactam/ β-lactamase inhibitor 
combinations are generally effective against organisms possessing a single ESBL; 
however, it has become the case that many organisms now produce multiple 
ESBLs,87–90 thereby reducing the effectiveness of such combinations. A 1994-1998 
study involving isolates from 35 intensive care units in Europe showed a rise from 31 
percent to 63 percent resistance to piperacillin-tazobactam β-lactam/ inhibitor 
combination over the span of that four year period.91 Evidenced in vitro, the 
carbapenems (imipenem, meropenem, ertapenem) have the most reliable activity 
against ESBL-producers as they are stable to hydrolytic activity by these enzymes. 
Cephamycins (alpha-methoxy cephalosporins modified at the 7-position carbon) have 
also shown stability toward the ESBLs; however, ESBL-producers tend to lose outer 
membrane proteins that lead to an ESBL-unrelated form of resistance to these 
antibiotics. 
 
Serious infections that include the presence of ESBL-producers should not be treated 
using third-generation cephalosporins: elevated cephalosporin MICs (4-8 μg/ mL) 
that still lie within the susceptible range can result in high failure rates.92–94 Though 
stochastic modeling studies of cefepime (a fourth-generation cephalosporin) have 
suggested high probability of successful pharmacokinetic/ pharmacodynamics target 
achievement,95 empirical data gained from clinical studies has been limited.94,96 
However, a randomized trial of cefepime versus imipenem for hospital-acquired 
pneumonia showed perfect clinical response (100 percent, 10 of 10 patients) to the 




cohort of patients infected by ESBL-producers.97 As a rule of principle common 
among many extended-spectrum cephalosporins, MICs for the antibiotic rise in 
tandem with the inoculum of the infecting organism.98–100 CTX-M-type ESBL 
producers tend to more frequently exhibit resistance activity toward cefepime,101 as a 
result, cefepime should not be used as first-line therapy against ESBL-producers. The 
recommended treatment for cefepime for organisms showing any in vitro MIC 
activities below a certain threshold (<2 μg/mL) is either high dosage (≥2g twice a 
day) or in combination with amikacin.102,103 
 
Cephamycins are also not recommended as a first-line therapeutic in ESBL-producing 
infections. Despite having reportedly good in vitro activity in the treatment of ESBL 
producers,104–106 use of cephamycins (including cefoxitin) have resulted in treatment 
failure and relapse of infection due to selection of porin resistant mutants during 
therapy. Furthermore, treatment of Klebsiella pneumoniae infection outbreak using 
combined cephamycin and carbapenem has been faced with resistant organisms.105  
 
Even in combination with β-lactamase inhibitors, β-lactam MICs rise in tandem with 
rising inoculum.100 Since ESBL-producers also often still harbor the parent enzymes 
(e.g., TEM-1, SHV-1), hyperproduction of these classical β-lactamases together with 
porin loss can result in decreased efficacy of β-lactamase inhibitors. Carbapenems 
have been shown to be more effective than β-lactam/ β-lactamase inhibitor 
combinations in some animal studies in the treatment of ESBL-producing 




lowered probabilities of reaching targets correlated with success; clinical experience 
with the drug-inhibitor combinations is limited. Therefore, drug-inhibitor 
combinations are also not recommended as the first line of treatment for serious 
infections with ESBL-producing organisms.95 
 
Other clinically relevant antibiotics. Quinolones have previously been shown to be a 
treatment of choice for complicated urinary tract infections with ESBL-producers 
when there is no detectable in vitro resistance. However, in vitro resistance is on the 
rise, and the development of newer quinolones are of marginal benefit. Carbapenems 
have been found to be equivalent or of greater effectiveness when compared to 
quinolones.103,108–111 
 
2.2 Βeta-lactamase enzymes 
2.2.1 Molecular mechanism 
This dissertation will focus on the most prominent and therefore most important mode 
of β-lactam resistance, namely, the production of β-lactamases. These enzymes are 
able to hydrolyze the β-lactam ring through a similar acylation mechanism to render 
the antibiotic inactive toward PBP targets. However, unlike PBPs, the structure of β-
lactamases enables them to coordinate a water molecule in the hydrolysis of the 
acylated substrate from their active site, thereby allowing them to turn over more β-





ESBLs, most of which are derived from classical TEM and SHV lineages of β-
lactamase, are of increasing concern.113  A few key features that distinguish ESBLs 
from typical β-lactamases is that ESBLs possess a number of mutations allowing 
them to hydrolyze expanded-spectrum β-lactam antibiotics. This functional expansion 
of hydrolytic ability is accompanied by a physical expansion of the active site that 
allows for the steric accommodation of extended-spectrum β-lactams having bulkier 
side chains; however this physical expansion may also result in increased 
susceptibility of the ESBL active site to binding by β-lactamase inhibitors.114 ESBLs 
do not exhibit activity against the cephamycins (alpha-methoxy cephalosporins). 
Interestingly, though most ESBL-expressing strains are thusly susceptible to 
cephamycins, the loss of an outer membrane porin protein may thereby confer 
compensatory resistance to cephamycins such as cefoxitin and cefotetan.104,115,116 
 
It is also important to note two other common modes of β-lactam resistance:  
Altered PBPs exhibiting lower affinity for β-lactam antibiotics. Mutations in the PBPs 
of certain species such as Streptococcus pneumonia and Staphylococcus aureus have 
exhibited some resistance to inactivation by penicillins, and their continued function 
may compensate for inactivated PBPs117. 
Diminished or eliminated expression of outer membrane proteins (OMPs). Gram 
negative bacteria have been found to lower or eliminate the expression of OMPS in 






2.2.2 ESBL producers 
The greatest threats among microorganisms are Gram negative producers of ESBL 
and include include Acinetobacter baumannii, Pseudomonas aeruginosa, 
vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus 
aureus (MRSA), and Aspergillus spp.119 Gram positive bacteria, especially 
Staphylococcus aureus and Enterococcus spp. pose major threats to antibiotic 
treatments, though this affront is relatively still under control as the majority of 
resistance is via horizontally acquired mec genes that encode modified PBPs (PBP2A 
in the case of MRSA) that have low affinity to “conventional” β-lactams (penicillin-
like antibiotics).117 Though widespread in its dissemination, MRSA can still be 
combatted by a variety of drugs including the glycopeptides and later-generation β-
lactams (cephalosporins).33 
 
Conversely, Gram negative bacteria are yet particularly worrisome, presenting a more 
serious challenge in facing the antibiotic crisis. They are especially prevalent in 
hospital and community settings, with Pseudomonas aeruginosa, Acinetobacter spp., 
and Enterobacteriaceae (Klebsiella pneumoniae) representative of nosocomial 
infections. In the community, Escherichia coli is the main producer of extended-
spectrum ESBLs, and Neisseria gonorrhea has developed chromosomally-encoded 
resistance to expanded-spectrum cephalosporins, including ceftriaxone.81 
The prevalence of β-lactamases have been fueled by the plasmid capture of normally 
chromosomal genes from Enterobacter cloacae, Citrobacter freundii, or P. 




labile Klebsiella pneumoniae or Escherichia coli against both earlier (alpha-methoxy-
β-lactams cefoxitin, cefotetan) and later generation cephalosporins (oxyimino-β-
lactams cefotaxime, ceftriaxone, and ceftazidime).120 ESBL-producing bacteria that 
express resistance (or reduced susceptibility) phenotypes to the oxyimino-
cephalosporins (e.g., cefotaxime, ceftriaxone, ceftazidime) are most largely 
represented by Enterobacteriaceae, namely Eschericia coli and Klebsiella 
pneumoniae. These two bacterial species are the main sources of community- and 
hospital-acquired infections.121 Carbapenem resistant Enterobacteriaceae (CRE) are 
one of the latest challenges facing human health. Some carbapenemase-producing 
strains have become resistant to most or all available antibiotics, causing infections 
extremely difficult to treat, and in some cases can contribute to death in up to 50% of 
infected patients.47,122 ESBL-producing (non-carbapenemase) Enterobacteriaceae are 
already responsible for 26,000 hospital-acquired infections, resulting in 1,700 deaths 
per year.123 
 
Here we focus on Gram negative pathogenic bacteria whose main resistance strategy 
is the production of extended-spectrum β-lactamase (ESBL). As some physicians 
recognize cephalosporins’ role in ESBL selection, so have they begun reverting to 
older antibiotic combinations for community-acquired pneumonias or surgical 
prophylaxis.72–74,77 Hospitals exhibit a greater concentration of resistant coliforms that 
can disseminate throughout the community environment.90,108 Therefore, in addition 
to eliminating cephalosporins as the prophylaxis of choice, further reduction of 




arsenal. Though ESBL producers can be inhibited by such remaining newer 
cephalsporins as cefepime, it must be ensured as the best choice before treatment.35 
 
2.2.3 Classification 
Functional and molecular grouping. Most ESBLs are considered as Ambler’s 
molecular class A,124 a key feature of which is possession of an active site serine 
residue, preferential hydrolysis of penicillins, and a molecular weight of 
approximately 29 kDa.125 Ambler classification differentiates ESBLs by amino acid 
sequence similarity, and class A includes families such as TEM-1, SHV-1, and S. 
aureus penicillinase, yet it does not sufficiently differentiate many types of class A 
enzymes. More recently, a classification scheme devised by Bush, Jacoby, and 
Medeiros uses the biochemical properties of the enzyme (i.e., substrate/ inhibitor 
profile) in addition to molecular structure and nucleotide gene sequence (for 
sufficient characterization of ESBLs by lineage origin) to classify ESBLs into distinct 
functional groups.126 Following this scheme, ESBLs are defined under functional 
group 2be as β-lactamase enzymes capable of hydrolyzing oxyimino-cephalosporins 











Table 2.1. An abridged table comparison of Amber and Bush classifications of ESBL. 
 
2.2.4 Classical origins of ESBL 
TEM β-lactamase family. TEM-1, the classical parent version of this β-lactamase 
family, is the most commonly encountered β-lactamase in Gram negative bacteria, 
accounting for up to 90% of ampicillin resistance in E. coli.113 It also accounts for 
increasing incidences of ampicillin and penicillin resistance in H. influenzae and N. 
gonorrhoeae. In addition to penicillins, TEM-1 is active against first-generation 
cephalosporins such as cephalothin and cephaloridine. TEM-3, first reported in 1989, 
is the first TEM-type to display the ESBL phenotype;127 since this first report over 90 
additional TEM derivatives have been described, the majority of which are ESBLs, 
some of which are inhibitor-resistant enzymes. 
 
SHV β-lactamase family. K. pneumoniae are the main genetic reservoirs of the SHV-1 
β-lactamase which accounts for up to 20% of the plasmid-mediated ampicillin 
Classification Description 
Ambler Class A/ 
Bush Group 2 
Penicillinases susceptible to β-lactamase inhibitors. 
Ex: S. aureus PC1 (Group  2a); E. coli, K. pneumonia 
TEM-1, SHV-1 (Group 2b) 
Ambler Class B/ 
Bush Group 3 
Carbapenemases, metallo-β-lactamases (MBLs), require 
Zn2+ atoms, resistant to clavulanic acid, sulfones. 
Ex: P. aeruginosa IMP-type, VIM-type, SPM, NDM 
Ambler Class C/ 
Bush Group 1 Cephalosporinases. Resistance to penicillins, β-lactamase 
inhibitors, cefoxitin, cefotetan, ceftazidime, ceftriaxone, 
cefotaxime. 
Ex: Chromosomally encoded AmpC (C. freundii, E. 





resistance in the species,128 with many strains integrating the blaSHV-1 gene into their 
chromosome.113 Unlike TEM-types, there exist relatively fewer derivatives of SHV-
type β-lactamases, and the changes that do give rise to derivatives occur in fewer 
positions within the structural gene. 
 
CTX-M β-lactamase family. This plasmid-encoded family of ESBL is characterized 
by their ability to preferentially hydrolyze cefotaxime, and have been identified in 
Salmonella enterica (Typhimurium) and E. coli among other Enterbacteriaceae. 
Prominent members of this enzyme family include CTX-M-1, CTX-M-2, CTX-M-10, 
and Toho enzymes 1 and 2.129,130 The CTX-M-type family is more genealogically 
distinct from TEM- or SHV-types, only showing approximately 40% homology.131 
Interestingly, studies comparing the genetics between CTX-M-type ESBL and AmpC 
of Kluyvera ascorbata have provided evidence that there is a high degree of 
homology between the CTX-M-type plasmids and chromosomally encoded AmpC 
enzymes, suggesting the chromosomal origination of the former from the latter.132 
Kinetic studies show CTX-M-type ESBLs hydrolyze cephalothin or cephaloridine 
(first-generation cephalosporins) more efficiently than benzylpenicillin, in addition to 
preferentially hydrolyzing cefotaxime over ceftazidime. Importantly, though they 
exhibit low-level activity against cefotaxime, this is not sufficient to display a 
survival resistance phenotype. The Ser-237 residue present in all CTX-M enzymes 
plays an important role in their extended-spectrum activity.133 The nonessential Arg-
276 residue, which is equivalent to the Arg-244 residue in TEM- and SHV-type 




oxyimino-cephalosporins.134 Toho-1 crystallographic studies (CTX-M family) have 
suggested increased flexibility of the CTX-M-type (thanks to marked differences in 
the β-3 strand and omega loop compared to other class A β-lactamases), and 
attributed the extended-spectrum phenotype to the lack of hydrogen bonding near the 
omega loop.135 Notably, CTX-M-types are better inhibited by tazobactam than other 
β-lactamase inhibitors sulbactam and clavulanate.129,131,136,137 
 
OXA β-lactamase family. Here we will briefly mention this genetically unrelated 
(with respect to TEM-, SHV-, and CTX-M-types) but growing family of ESBLs. 
These ESBLs belong to the molecular class D (Ambler) and functional group 2d 
(Bush-Jacoby-Madeiros). They have high hydrolytic activity against oxacillin and 
cloxacillin, from whence they derive their name, and also confer resistance to 
ampicillin and cephalothin (first-generation cephalosporin); they are additionally 
poorly inhibited by clavulanic acid. OXA-type ESBLs are mainly found in P. 
aeruginosa but also in many Enterobacteriaceae. Interestingly, OXA-type ESBLs 
provide only weak resistance activity against the oxyimino-cephalosporins when 
cloned into E. coli but fairly high-level resistance in P. aeruginosa.138 In a similar 
story to the previously mentioned ESBLs, whereas most OXA-types exhibit activity 
against ceftazidime, OXA-17 in particular appears to have traded off its ceftazidime 
activity to take on cefotaxime and ceftriaxone resistance.139 
 
AmpC β-lactamases. AmpC β-lactamases are capable of hydrolyzing the alpha-




sulbactam. AmpC expression is governed by chromosomal determinants and 
overproduction of AmpC is known to produce braod-sectrum resistance to both 
cephamycins and oxyimino-β-lactams. 
 
Class B metallo-β-lactamases (MBLs). To address the growing concern of 
carbapenem resistance, we must discuss their culprits, the highly transmissible 
plasmid-mediated metallo-β-lactamases capable of inactivating this entire class of 
antibiotics. MBLs boast great breadth in their substrate activity spectrum and can 
catalyze the hydrolysis of virtually all β-lactam antibiotics with the exception of 
monobactams.140 Unlike the class A serine β-lactamases, MBLs are not inhibited by 
clavulanate, sulbactam, or tazobactam.141,142 Interestingly, they are additionally not 
effectively inhibited by NXL-104, an inhibitor of class A and C enzymes currently in 
clinical trials.143 However, as they rely on metal ions for their activity, MBLs are 
accordingly inhibited by metal chelators such as EDTA.141 
 
Genetics. Initially discovered nearly half a century ago, and found to be 
chromosomally encoded in non-pathogenic organisms,144,145 MBLs have in recent 
decades become a critical threat to human health with the advent and spread of IMP- 
and VIM-types in Gram negative pathogenic Enterobacteriaceae, P. aeruginosa, and 
A. baumanii.146,147 Additionally, the genetic promiscuity and transmissibility of IMP- 
and VIM-type enzymes is due to their encoding as gene cassettes residing within the 
integron structures of other resistance genes, and are associated with transposons that 




essentially genetic stockpiles in bacteria that can undergo site-specific promoter 
recombination to allow expression of new genes. The activation and movement of 
resistance genes within plasmids is facilitated by integrons; once on plasmids, the 
transfer of resistance genes between different bacteria is achieved with much greater 
ease compared to genes that are chromosomally encoded.149 That this identifiable 
phenomenon plays a critical role in the emergence of so-called multidrug resistant 
“superbugs” in the wake of carbapenem treatment failure thus becomes obvious and 
undeniable. 
 
The more recent NDM-1 MBL first discovered in 2008 in Klebsiella pneumonia and 
E. coli demonstrates the dissemination potential of MBLs. Found on several plasmid 
types, blaNDM-1 can be transferred among Gram negatives by conjugation. Though not 
associated with integron structures, NDM-1 nonetheless has rapidly spread 
worldwide,122,150 perhaps facilitated by its association with transfer-promoting 
insertion element ISAba125. 
2.3 Genetic detection of ESBL 
2.3.1 Genetics and evolution of ESBL 
As an overview, we will begin with some important behavioral features of ESBL 





• The β-lactamase gene (bla) can be encoded chromosomally, on plasmids, or 
on transposons. Their expression behavior (constitutive or inducible) depends 
on the genetic environment in which they are situated.  
• Extended-spectrum β-lactamases give rise to resistance against oxyimino-
cephalosporins (e.g., cefotaxime, ceftazidime, ceftriaxone, and aztreonam, an 
oxyimino-monobactam, etc.). 
• Plasmid-mediated enzymes confer resistance to alpha-methoxy-
cephalosporins, such as cephoxitin and cefotetan, as well as the oxyimino-β-
lactams. These are the class C β-lactamases which are normally 
chromosomally encoded in Gram negatives. 
• Class B metallo-β-lactamases confer resistance to the carbapenems such as 
imipenem and meropenem, and include the oxyimino- and alpha-methoxy-
cephalosporins. 
• Chromosomally encoded class A extended-spectrum enzymes are found in 
Klebsiella oxytoca and other nosocomial pathogens, though these are outside 
the relevant scope of this review and will not be discussed here. 
 
TEM-1 is the most common plasmid mediated β-lactamase in enteric organisms 
except in Klebsiella pneumoniae (SHV-1 dominates). Single amino acid substitutions 
may yield identical enzymatic properties, but in some cases may result in low-level 
enhancement of activity toward a few oxyimino-cephalosporins, as in the case of 
TEM-7 or TEM-12 which differ by Ser substitution at position 164, or TEM-11 




toward cefotaxime, ceftazidime, and aztreonam.151 Notably, marked relative increases 
in activity toward ceftazidime and aztreonam occur when the 164-positional 
substitutions are accompanied by one of the following: Lys-104, Lys-240 or Thr-237, 
and Lys-240 appearing in the arising ESBLs TEMs -5, -6, -9, -10, -16, -24, or -26. 
Interestingly, these subsitutions are always associated with greater ceftazidime 
activity over cefotaxime.152 In contrast, TEMs -3, -4, and -8, which possess a Ser-238 
residue change, exhibit higher activity against cefotaxime over other oxyimino-β-
lactams. Enzyme-substrate activity trends of striking similarity also appear within the 
SHV family with Ser-238 association with higher cefotaxime hydrolysis over 
ceftazidime, and Lys-240 (SHV-4, SHV-5) correlating to a concomitant increase in 
ceftazidime activity. 
 
It is of high importance to note that mutations yielding an advantageous increase in 
relative activity is in fact a double-edged sword: the broader substrate specificity 
afforded by substitutional changes from the classical enzymes, extended-spectrum β-
lactamases suffer from lowered catalytic efficiency. TEM-1 is a wonderfully efficient 
enzyme153; kinetic studies of extended-spectrum TEMs -3, -5, -9, and -10 reveal they 
only exhibit 0.4 to 2.2% of the specific activity of the classical TEM-1 enzyme.154 In 
nature, bacteria compensate for this grave loss in catalytic efficiency by pushing the 
metabolic production of these broader β-lactamases into overdrive. To do this, more 
efficient promoter-possessing genes such as TEM-2 are 4 to 30 times more efficient 
than TEM-1, making it the likely progenitor of the later ESBL evolutions.154,155 




insertion sequence IS1 can also increase expression efficiency. Enzyme 
hyperproduction by way of new combinations of promoter elements can play a 
fundamental role in increasing resistance; hyperproduction of SHV-1 enhances 
resistance to ceftazidime and aztreonam.156 
 
The genes for TEM- and SHV-type ESBLs are typically encoded by large, 
multiresistant plasmids thought to carry associated virulence factors that can aid 
bacterial colonization and dissemination.157 Interestingly, and perhaps as a result, 
strains producing ESBL often also produce TEM-1,158 potentially to compensate for 
the loss in activity concomitant with substrate spectrum expansion. Yet this often 
reduces the effectiveness of β-lactam-inhibitor combination treatments, as in the 
example of E. coli expressing TEM-3, TEM-7, and SHV-4, but also TEM-1 thus 
reducing or completely nullifying synergistic effects of ceftazidime with added 
inhibitor sulbactam. The majority of SHV-type derivatives exhibit the ESBL 
phenotype, and one variant, SHV-10, which possesses a glycine 130 to serine 
substitution, is reported to be inhibitor-resistant.159 Importantly for purposes of 
enzyme-substrate behavior prediction, the Ser140Gly mutation appears to override 
the strong ESBL phenotype seen in SHV-type enzymes with the Gly238Ser and 
Glu240Lys mutations. SHV-type ESBLs though mainly seen in K. pneumoniae have 
also been observed in Citrobacter diversus, E. coli, and P. aeruginosa.160–163  
 
It is believed that fluctuating selective pressure from multiple β-lactam agents within 
an institutional setting are responsible for ESBL incidence rather than selection by a 




for TEM-type ESBLs, their spread to other Gram negatives is occurring with 
increasing frequency with reports in Enterobacteriaceae such as Enterobacter 
aerogenes, Morganella morganii, Proteus mirabilis, Proteus rettgeri, and Salmonella 
spp., as well as non-Enterobacteriaceae Gram negatives (e.g., TEM-42 in P. 
aeruginosa; TEM-17 in Capnocytophaga ochracea).101,164–168 
 
2.3.2 Genetic methods of antibiotic resistance detection 
Since its inception in 1985, polymerase chain reaction (PCR) has proven to be a 
powerful technology for the precise detection of specific gene sequences. This tool 
can be used for the identification of pathogens and characterization of resistance and 
virulence factors, shedding light on not just etiology but also phylogeny for 
classification purposes. As such, the detection of the presence of resistance genes can 
provide crucial evidentiary support for antimicrobial therapies in the clinic, and many 
techniques exist for this purpose. However, there exists a strong caveat emptor of 
admonition: the confirmed presence of a resistance gene within a clinical sample does 
not necessarily portend treatment failure.169 Additionally, there are many challenges 
in the genetic detection of resistance determinants, including: false-positive results 
due to silent gene or pseudogene amplification; low sensitivity on mixed flora 
samples due to PCR inhibition; susceptibility to contamination with extraneous or 
residual nucleic acids; generation of false-negatives due to primer binding site 
mutations; unwieldiness in screening for new resistance mechanisms in general 





Here we will briefly mention a few developed methods providing greatest utility for 
the genetic detection of antibiotic resistance. 
 
PCR (polymerase chain reaction). This very common standard methodology can be 
applied to colony hybridization for the detection of OXA-type ESBL. DNA from 
positive isolates is extracted, PCR amplified using OXA-specific primers, and 
digested using restriction endonucleases; restriction fragment sizes are compared to 
distinguish groups of OXA-related genes. Though this technique does not directly 
identify specific OXA genes present, it can distinguish between ESBL and non-ESBL 
OXA-type genes. 
 
PCR-Restriction Fragment Length Polymorphism (PCR-RFLP). This is one of the 
simplest methods most commonly used to detect SHV derivatives by identifying the 
specific mutation at peptide position 238.173 The extracted DNA is first amplified by 
PCR, then digested with restriction enzyme NheI to detect the G to A nucleotide 
change that gives rise to the G238S amino acid substitution. This substitution is 
common in many early variants of the SHV-type ESBLs. 
 
PCR-Single-Strand Conformational Polymorphism (PCR-SSCP). Able to detect 
single base mutations within the blaSHV gene
174,175, this test first generates a 475-bp 
amplimer using oligonucleotide primers internal to the coding sequence of the blaSHV 
gene, then is digested with restriction enzyme PstI. Fragments are run on a 20% 




amplimer fragments can be used to identify SHVs -1 through -5, and SHV-7. 
Combining PCR-SSCP and PCR-RFLP can allow for the identification of a total of 
17 SHV genes.176 
 
Ligase Chain Reaction(LCR). LCR can be used to identify DNA sequences by a 
single base pair difference. This method uses a thermostable ligase and four 
oligonucleotide primers complementary to the target sequence that hybridize adjacent 
to each other. Subsequent amplification will only occur if there is no base mismatch, 
which allows the ligase to act to produce an amplifiable sequence. LCR is performed 
by first denaturing the target DNA containing the blaSHV gene, then allowing 
biotinylated primers to bind, detecting mutations at four positions. An enzymatic 
reaction with NADPH-alkaline phosphatase allows for detection readout. Because 
this detection methodology identifies single base pair differences, new 
oligonucleotides must be designed for every suspected single nucleotide 
polymorphism (SNP), posing a great feasibility challenge for practical 
implementation of LCR into clinical workflows. 
 
Sequencing. Nucleotide sequencing is the fall-back standard method to determine 
presence of a specific β-lactamase gene. Many methods exist for this purpose, but 
high skill is required for processing and reading of sequencing autoradiographs.177 
Next-Generation Sequencing (NGS) holds great promise in providing resistance gene 





2.3.3 Considerations in the genetic detection of ESBL in Gram negatives 
The proliferation of new subtypes within each ESBL family giving rise to an ever-
increasing number of variants poses a gargantuan challenge to genetic methods of 
ESBL mediated resistance detection as these methods face inherent limitation in their 
ability to encompass the full range of ESBL morphs. As such, the identification and 
monitoring of ESBL by genetic methods should be reserved for reference laboratories 
receiving difficult-to-type strains often exhibiting complex resistance. For molecular 
epidemiological purposes, PCR-RFLP is viewed as one of the most appropriate 
techniques for the most common ESBL types,179 as type-specific PCRs combined 
with PCR-RFLP can cover a number of TEM, SHV, and CTX-M subtypes.176,180–182 
Importantly, as phenotypic methods face difficulties from variable levels of resistance 
expression, genotypic methods carried out in reference laboratories should 
accompany phenotypic assessment, especially to discern any discrepancies which 
may arise between the two.183 Still, direct sequencing remains the gold standard for 
identifying any unknown amplification products of a given reaction. As the 
automation of running and analysis of sequence gels advances, this provides an 
expansive method for determining any resistance gene or mutation.184 
 
2.4 Phenotypic detection of ESBL 
2.4.1 Clinical & Laboratory Standards Institute (CLSI) Laboratory Guidelines. 
Documents provided by CLSI have for many years provided laboratories with 




covered by the guidelines include most relevant drugs to test, report updates on 
specific organisms, quality control measures for assurance in accuracy and 
reproducibility of results, MIC breakpoints and interpretive criteria for disk diffusion 
zone measurements.185,186 The M2 document provides performance criteria for disk 
diffusion tests and the M7 document details performance criteria for MIC testing. 
These two documents address testing of common, rapid-growing aerobic bacteria 
(e.g., staphylococci, enterococci, Enterbacteriaceae, and specific species of 
Pseudomonas, Acinetobacter, Burkholderia cepacian, Stenotrophomonas maltophilia, 
Vibrio cholerae, Haemophilus influenzae, Neisseria gonorrhoeae, Streptococcus, and 
Neisseria meningitidis). The M100 is a supporting document containing supplemental 
tables with recommended drugs for testing and reporting, interpretive breakpoints, 
and quality control ranges.186 The M11 document details culturing and testing 
methodologies for anaerobic bacteria, such as agar and broth microdilution for MIC 
determination.187  
 
CLSI Breakpoint Methodology. Breakpoint determination or MIC interpretive criteria 
for new antimicrobials, organisms yet to be characterized, or modifications to 
previous criteria are established as outlined by the CLSI publication (document M23-
A2) based on four types of required data: (1) establishment of the new antimicrobial 
agent’s MIC performance in wild-type isolates that lack known resistance 
mechanisms, and comparisons with MIC performance in strains of isolates that have 
known resistance mechanisms affecting the antimicrobial agent’s drug class; (2) 




patients, and comparisons with the examination of pharmacokinetics of the drug in 
body fluids and tissues of in patients with infections of various types; (3) 
pharmacokinetic studies (empirical evidence with the option of mathematical 
modeling) to enable the observation of peak serum level of the drug and its potential 
maintenance at levels above proposed MIC breakpoints (especially useful for β-
lactams and glycopeptides); (4) exhaustive review of clinical and bacteriological 
response data collected over large clinical trials performed regarding a new 
antimicrobial agent to substantiate potential U.S. Food and Drug Administration 
(FDA) approval. 
 
2.4.2 Gold standard techniques for ESBL determination 
To address this need, the standards for testing established since the early days of 
resistance incidence rely on several methods which will be described in this section. 
 
Double-disk synergy test (DDST). The inception of this test began in epidemiological 
studies on the spread of ESBL-producing Enterobacteriaceae in French hospitals in 
efforts to distinguish observed cefotaxime resistance as due to ESBL production or 
cephalosporinase overproduction.188 This test is based on the synergy between a third-
generation cephalosporin and clavulanate. The two are placed at a certain distance 
from each other on a lawn of petri dish cultured from isolated single colonies derived 





Hyperproduction of cephalosporinase can confound results attempting to pinpoint 
ESBL presence; the use of a fourth-generation cephalosporin (cefepime) that is less 
easily inactivated by cephalosporinase than ESBL can therefore improve the detection 
of synergetic effects with clavulanate. Similarly, specific detection of ESBL over β-
lactamase classes capable of hydrolyzing both third-generation cephalosporins and 
carbapenems (metallo-β-lactamases) can be performed by the inclusion of EDTA to 
chelate essential metal ions in the synergetic test alongside clavulanate189.   
 
ESBL Etest. These tests are designed to quantify the synergy between extended-
spectrum cephalosporins and clavulanate. They contain gradients of cephalosporin 
either alone on one end of the strip or in combination with clavulanate on the other 
end. Positive results are determined by a MIC ratio of 8 or more (three or more two-
fold dilution steps) with clavulanate, the appearance of a rounded “phantom” zone 
below the lowest antibiotic concentration, or a deformation of the inhibition ellipse. 
The latter two indicate the likely presence of ESBL production. ESBL detection in the 
presence of metallo-β-lactamases can be determined using Etests containing EDTA 
and comparing the inhibition zones corresponding to similar MIC dilution zones as 
the typical Etest. Interpretation of these results can be variable and requires training 
for higher accuracy, and suffers from a 30% failure rate.190 
 
Combination Disk Method. This method involves measurement of the inhibition 
zones around a cephalosporin disk compared to the same disk containing clavulanate. 




diameters are considered positive for ESBL production. The presence of clavulanate 
may result in an enlarged inhibition zone (5 mm or more) for ESBL-producing 
organisms in comparison to a smaller inhibition zone (1 mm or less) in AmpC 
overproducers. 
 
Distinguising from cephalosporinase overproduction (AmpC). The standard DDST 
cannot provide distinguishing information between cephalosporinase overproducers 
and ESBL producers. As a result, in ESBL producers, a modified Etest performed on 
cloxacillin-containing agar will show positive results (MIC ratios 8 or greater) for an 
Etest strip containing the cefepime-clavulanate combination. In contrast, ESBL non-
producers will show non-interpretable results for Etest strips comtaining cefepime-
clavulanate or cefotaxime-clavulanate without the presence of cloxacillin in the 
media. 
 
Automated methods. Two prominent automated MIC determination systems are the 
VITEK 2 ESBL test (bioMérieux, Marcy l’Etoile, France) and Phoenix ESBL test 
(Becton Dickinson, Sparks, MD, USA). These systems both rely on the bacterial 
growth response to a panel of expanded-spectrum cephalosporins (cefepime, 
cefotaxime, ceftazidime) with or without clavulanate. Turbidimetric measurements 
are made at regular intervals following inoculation, and a computerized system 
compares the proportional reduction of cell growth between wells containing the 
cephalosporin alone or with clavulanate to determine ESBL status. Broth 




correspond to inhibition zones from disc diffusion test methods within the range of 
resistance producers (0.5-2 mg/L), yet may still result in clinical failures; thus, 
reliable detection still remains of high importance.191,192 
 
Though the standard methodologies outlined above do provide high reliability in 
susceptibility testing, MIC determination, and often also bacterial species 
identification, they suffer from the requirement of culturing, and can only be carried 
out in specialized, central laboratory spaces with highly trained personnel to operate 
sophisticated equipment, and have expertise in interpretive determination which is not 
always apparent (as in the case of inhibitory zones using DDST). Rather than solely 
relying on turbidimetric measurement, rapid determination can be aided by the use of 
chromogenic substrates that quickly produce measurable and sometimes visual 
readout in a more convenient format. In the next section we will detail the 
chromogenic substrates that have been developed as part of a toolkit for newer 
methods of phenotypic AMR detection. 
 
2.4.3 Newer methods in phenotypic detection 
Chromogenic cephalosporins. While the rate of hydrolysis of β-lactam compounds 
can be monitored by measuring the loss of absorbance at 235-260 nm (indicative of 
lactam bond cleavage), this method suffers from poor analytical sensitivity due to a 
few main factors: a) small molar extinction coefficients of the substrate (< 1000 M-1 
cm-1), b) short optical path lengths in microtiter assay plates (< 1 cm), and c) other 




substrates provide much higher extinction coefficients in comparison, often 
enhancing sensitivity one to two orders of magnitude. Further, chromogenic 
substrates are by definition within the visible range, making easy visual assessment a 
feature for higher concentration samples. 
 
Chromogenic substrates are designed by taking advantage of the cephem core’s β-
lactam ring opening mechanism as a trigger: intramolecular bond rearrangement will 
release “reporters” (chromogens or small molecules capable of downstream reaction) 
if the 3-position of the cephem ring is a methyl halide. CENTA (3-(4-nitro-3-
carboxyl-phenylthiol)-methyl-(6R,7R)-7-(2-thienyl-acetamido)-ceph-3-em-4-
carboxylate) is one such substrate (1 in Fig. 2.3). Upon hydrolysis, this substrate 
releases 2-nitro-5-sulfanylbenzoic acid, which has an absorbance peak at 405 nm. 
PADAC (2 in Fig. 2.3) is a similar substrate that releases N,N-dimethyl-4-[(Z)-
pyridin-2-yldiazenyl]aniline which has a maximum asorbance peak at 550 nm.193–195 
An interesting synthetic compound (3 in Fig. 2.3) releases ethanioic S-acid when 
hydrolyzed, resulting in a thiolate that can reduce tetrazolium salt in solution to form 
an insoluble colored precipitate as a cleavage activity readout.196,197 
 
Release of leaving groups on the 3-methyl of the cephem ring does not necessarily 
occur in a concerted fashion with regard to β-lactam ring opening.198,199 
In the case that the 3-methyl within the cephem ring is designed as a continued 
alkene, without a halide but rather a carbon, designed chromogenicity may still occur 




measurable. (4-9 in Fig. 2.3) shows styryl groups at the 3-methyl position 
functionalized with various chromophores. One of the best-known of this type is 
Nitrocefin (4 in Fig. 2.3) which displays a striking visual color change from an initial 
maximal absorbance at 386 nm that shifts to 482 nm upon hydrolysis. As Nitrocefin 
is cleavable by classical β-lactamases such as TEM-1, toward an attempt to make a 
diagnostic substrate that can differentiate ESBL, compound (9 in Fig. 2.3) has been 
designed to possesses an oxyimino modification similarly to third-generation 
cephalosporins. Nitrocefin (4 in Fig. 2.3) and Chromacef (8 in Fig. 2.3) have been 
used in screening studies of metallo-β-lactamase inhibitors, highlighting the 







Figure 2.3. Chromogenic cephalosporin substrates for phenotypic detection. 
 
 
Chromogenic substrate containing media. These are considered the latest generation 
in the “rapid” culture-based detection as they are designed to combine ESBL 
detection with organism identification. Engineered chromogenic substrates build up 




interest, allowing easy visual differentiation of (potential) pathogens from non-
expressers within a culture plate.205 However, chromID ESBL displays low 
specificities (11-44%) due to interference from the growth of AmpC-
overproducers,205–208 and Brilliance ESBL suffers from similar complications. The 
incorporation of cloxacillin in EbSA demonstrated significant suppression of AmpC 
producers and higher specificities over chromID ESBL (78% versus 44%).206 Growth 
of non-ESBL K1-OXY penicillinase overproducing K. oxytoca and some OXA-30 
penicillinase-producing E. coli also compromises the specificities of chromID ESBL 
and Brilliance ESBL. CHROMagar CTX which specifically targets CTX-M-type 
ESBLs showed 100% sensitivity; however, this was reduced to 64% when non-CTX-
M-type ESBLs were recovered. Notably, only 14% of AmpC producers grew on 
CHOMagar CTX versus 76% on chromID ESBL, indicating suppression of AmpC 
producers in the former media.209 
 
Currently commercially available chromogenic media include chromID ESBL 
(bioMérieux), Brilliance ESBL (Oxoid Ltc., Basingstoke, UK), and CHROMagar 
ESBL (CHROMagar, Paris, France). These are offered as either ready-to-use media, 
or a proprietary selective mix that is added to a commercial product such as 
CHROMagar Orientation agar base. CHROMagar also provides a product for 
detection of CTX-M producers, the CHROMagar CTX supplement that is added to 
the CHROMagar ECC base. These media have been shown to have almost uniformly 




Antibiotics as selective agents. Media selectivity can be tuned using antibiotic 
combinations at certain concentrations to suppress the growth of Gram positive 
organisms and yeasts in order to select for ESBL producing Gram negatives. Though 
full combinations are not entirely disclosed by the company, cefpodoxime (4 μg/ mL) 
is the cephalosporin of choice to select for ESBL producers and is incorporated into 
the chromID ESBL and Brilliance ESBL products. The reason for this choice is 
because cefpodoxime is known as a reliably selective substrate for most TEM- and 
SHV-derived ESBLs, and is preferred for its effectiveness in being a single selective 
substrate; this is in constrast with ceftazidime which must be combined with 
cefotaxime for the reliable selection of CTX-M producers and ceftazidime-
hydrolyzing TEM-type variants. The superior performance of these commercial 
chromogenic media containing cefpodoxime has been demonstrated over MacConkey 
agar supplemented with ceftazidime (2 μg/ mL).208,208 However, the growth of 
cephalosporinase overproducers (AmpC and K1) has presented much challenge in the 
use of cefpodoxime disks, and as a result cefpodoxime concentration must be 
carefully chosen as MICs in the indeterminate (“ambiguous window”) range of 2-4 
μg/ mL for E. coli cannot rule our resistance mechanisms arising from changes in 
porin or AmpC overexpression states.210 The chromID ESBL product also 
incorporates additional antibiotics to allow better inhibition of adjunct flora.14 
 
Efficacy of chromogen combinations to differentiate genera/ species. ChromID and 
Brilliance ESBL contain chromogens that can differentiate E. coli from a grouping of 




One of the chromogens in chromoID ESBL is a substrate for β-glucuronidase that is 
highly specific to E. coli (indicated by development of colonies that are pink to 
burgundy in color); Brilliance ESBL agar contains chromogens that can also detect β-
galactosidase/ β-glucuronidase co-producers (indicated by the development of blue 
colonies, pink colonies if β-glucuronidase-only producer). Presence of KESC 
colonies are indicated by a green/ green-blue (due to β-galactosidase expression) or 
brown-green (due to β-glucosidase expression) on Brilliance and chromID ESBL. 
Additional supplementation with tryptophan can enable the detection of Proteus, 
Morganella, and Providencia (PMP grouping) that appear tan with a brown halo due 
to tryptophan deaminase production. 
2.5 Enzymology 
2.5.1 Motivation 
Enzymes from the different Ambler classes of β-lactamases hydrolyze β-lactam 
antimicrobial agents at different rates. Because β-lactamases can be encoded 
chromosomally, on plasmids, or encountered alongside a variety of resistance 
mechanisms that may be co-expressed, resistance determination via phenotypic 
measurement may give rise to a range of MIC values due to this continuum of 
antimicrobial activities. In this dissertation, resistance determination is evaluated 
through the characterization of readout modalities (e.g., colorimetric or fluorescence 
signal accumulation, enzyme-coupled redox activity for amperometric measurement, 
photon counts quantified by spectroscopic methods) in their responses to β-lactamase 




direct or indirect biochemical observation, enzyme activity will be expressed using 
the international convention in terms of unit activity (international unit, abbreviated 
as IU or just U), which is defined as the amount of enzyme that catalyzes the 
hydrolysis of one micromole of substrate (the β-lactam benzylpenicillin, also known 
as Penicillin G) per minute under standard conditions (aqueous buffer of neutral pH 
7.0 at 25 °C). 
 
2.5.2 Rationale 
In light of bringing our biochemical studies toward clinical relevance as established 
by gold standard methodologies, we must attempt to translate enzyme unit activity 
into terms approximating MIC. To do this, we will take into account substrate 
conversion rates described by enzymatic unit activity, and consider MIC as the 
primary determining factor of substrate transport equilibrium at the bacterial outer 
membrane-external media interface. 
 
Minimum inhibitory concentration (MIC) is defined as the lowest concentration of an 
antimicrobial agent (i.e., the β-lactam antibiotic in question) that will inhibit the 
visible growth of a microorganism after overnight incubation. Given this definition, it 
can be logically deduced that the microorganism in question would achieve growth at 
an antimicrobial concentration just below the MIC threshold. Therefore, we may 
conceive of this threshold as representing the cumulative whole of the 
microorganism’s resistance activities that enable its replicative survival. Though this 




resistance mechanisms), for demonstrative purposes we may model an initial 
translation of our in vitro biochemical analysis to clinical MIC under the assumption 
that 100% of the resistance activity present in a given test sample is due to β-
lactamase mediated inactivation of β-lactam antibiotics present in the test media (e.g., 
the cleavage of β-lactam derivative by ESBL). This implies that in order to survive, 
the theoretical bacterial strain (acquiring 100% of its resistance through ESBL 
production) must inactivate the antibiotic at the same rate at which it diffuses into the 
periplasm (site where the PBP targets reside), which is proportional to the 
extracellular concentration given by MIC, as described by Fick’s law of diffusion. 
 
2.5.3 Modeling 
Mathematical characterization of antibiotic penetration into the bacterial periplasmic 
space where they encounter ESBL can be related in terms of rates of drug diffusion 
across the outer membrane.211,212 These uptake rates are described as a permeability 
coefficient (P in nm s-1) according to Fick’s law of diffusion: 
V = P x A(So – Si) 
 where V is the rate of diffusion (nmol mg cells-1 s-1), A is the area of the cell surface 
per unit weight (nm-2 mg cells-1) through which antibiotic diffusion (flux) occurs, and 
So and Si are the substrate concentrations (nmol mL
-1) outside and inside the bacterial 
outer membrane, respectively, with their difference representing the concentration 
gradient.  
We can think of the flux based on concentration gradient (determined by MIC) to be 




be at equilibrium for the bacterial cell to maintain cell wall synthesis and survival. 
Therefore, assuming overall MIC (bulk media) remains constant, the flux over time 
would equal product generated over the same period of time. Product generation can 
therefore be considered in terms of IU, which would depend on the enzyme’s 







Chapter 3: Design and synthesis of ESBL detection substrates 
 
 
Figure 3.1. Cephem ring, structure, and positional numbering. 
 
Cephalosporins are a class of β-lactam antibiotics related to penicillins that also share 
the same four-membered β-lactam ring. Whereas penicillins possess a five-membered 
thiazolidine ring, the classical cephalosporins possess a six-membered 
dihydrothiazine (cephem) ring fused to the β-lactam. The cephem ring also possesses 
a double bond between the 3- and 4- position carbons, and a 4-position carboxylic 
acid (which becomes a carboxylate at physiological pH, aiding with solubility in 
aqueous environments).  
3.1. Rational design of detection substrates 
Basis. Our design of synthetic detection substrates is based on one well-known 
critical feature of the cephalosporin stereochemistry: the opening of the β-lactam ring 
in cephalosporins is associated with release of a suitable leaving group on the side 




nucleophile can occur as a base-catalyzed hydrolysis event (as seen in vitro), or as an 
acylation of the carboxypeptidase/ transpeptidase enzymes responsible for 
peptidoglycan synthesis in vivo (thus constituting the primary mode of action of β-
lactam antibiotics). Example leaving groups liberated in the breaking of the β-lactam 
ring are acetate, pyridine, and azide groups corresponding to antibiotics cephalothin, 
cephaloridine, and any 3-(azidomethyl)cephalosporin.37,213,214 An important property 
of the cephem structure that enables leaving group liberation is the functional group 
substitution at the 3-position which allows stabilization of a negative charge upon β-
lactam ring opening, an event occurring from breaking of the 1-8 amide bond. This 
negative charge stabilization aids an increase in the overall reactivity of the β-lactam 
ring, a property that can enhance interactivity of the cephalosporin with bacterial 
transpeptidase enzyme targets.106 Thus, previous substrates designed to assay the 
activity of β-lactamase have been based on the detection of leaving groups as the 
decomposition product. In this work we describe the employment of glucose and 
SERS-active benzylic molecules as leaving groups enabling ESBL reporting. 
Figure 3.2. Electronic rearrangement within the cephem core structure following ring opening via 





Leaving groups. Upon opening of the β-lactam ring, it is known that the departure of 
the leaving group is spontaneous.198 The electronic details describing the exact nature 
behind this spontaneous departure was initially thought to be reliant on a concerted 
mechanism based on quantum mechanical studies.215 However, leaving group 
elimination as a concerted event has since been countered by subsequent studies 
suggesting this is not a necessary case.199 By spectrophotometrically following 
PADAC (pyridine-2-azo-4’-(N’,N’-dimethylaniline) cephalosporin), an intermediate 
wherein the leaving group is still attached at the C-3 position post-ring opening has 
been observed. Though this implies PADAC’s leaving group is a poor one, further 
evidence suggests the departure of known good leaving groups such as acetoxy or 




Side chains. (Here we will refer to the side chains at the C-7 position as “amide” and 
the ones at the C-3 position as “leaving group”.) 
Figure 3.3 Antibiotics of different generations and their side chains corresponding to synthesized 
detection substrates. (Magenta colored groups indicate SERS-active or potentially SERS-active 
moieties). 
 
Our design of detection substrates was done with the intention that each would 
roughly correspond to a certain cephalosporin generation, and thus display specificity 
for narrow- versus extended-spectrum β-lactamases. As we can see in Fig. 3.3, the 




the amide side chain and an acetoxymethyl moiety (blue) as the leaving group. We 
correspondingly designed our Cep-diNTP SERS-active reporter substrate to have the 
same amide side chain as the first-generation cephalothin. Second-generation 
cefamandole has a (R)-mandelamido amide side chain and a N-methylthiotetrazole 
leaving group side chain; we began with a starting material (Fig. 3.5, 4-
Methoxybenzyl-3-chloromethyl-7-(2-phenylacetamido)-3-cephem-4-carboxylate, or 
“PMB-Cep-Cl”) with a similar (benzylacetyl)nitrile side chain which is not exactly 
the same as the first-generation cephalosporin but would perhaps experimentally 
show similar enzyme specificities (this has been confirmed in the following studies). 
Important to note is that the leaving groups also play an important role in the enzyme 
reactivity and thus also antimicrobial effects of cephalosporin antibiotics.216 Thus, it 
is necessary to acknowledge that changing the amide side chain in design approach 
for engineering enzyme specificity is inherently incomplete. Though Cep-pNTP and 
Cep-glucose share the same amide side chains, the differing leaving groups may also 
play a critical role in specificity in enzyme active site binding. Further, as thio-
glucose constitutes a poor leaving group whereas pNTP constitutes a good leaving 
group, the observable kinetics of spontaneous leaving group expulsion will be 






3.2 Reaction mechanisms 
3.2.1 Nucleophilic substitution (SN2 reaction)  
One step in the organic synthesis of our ESBL detection substrates relies on 
nucleophilic substitution of an alkyl halide at the 3-position of the cephem ring. 
Functionalization of the 3-carbon substituent with small molecules capable of ESBL 
reporting as the leaving groups occurs in an SN2-concerted displacement in which a 
potent nucleophile displaces the halide (Scheme 3.2.1). The nucleophile we employ 
for this scheme is the thiolate anion produced from 1-thio-β-D-glucose upon 
deprotonation with diisopropylethylamine (DIEA), a hindered base. The displacement 
of chloride results in 3-position carbon substituent functionalization of the 
cephalosporin core structure with thio-glucose as the R2 variable group. In terms of 
solvent choice, to enhance the reactivity of the nucleophile, an aprotic solvent is 
employed. Though solvent polarity is not as critical to SN2 reactions, the use of 
acetone allows facile solvation of the PMB-Cep-Cl starting material. 
3.2.2. Finkelstein exchange. 




Nucleophilic substitution can be carried out by alkoxides as well as thiolate-bearing 
ones. However, as alkoxides are less nucleophilic than thiolates, the SN2 reaction can 
be enhanced by the inclusion of a Finkelstein exchange step in which the chloride 
leaving group is replaced by iodide. In our synthesis scheme, reaction of the PMB-
Cep-Cl starting material with sodium iodide (NaI) for approximately one hour in 
acetone at room temperature is sufficient for completion of the Finkelstein exchange; 
displaced chloride anions form an ionic salt with the sodium cations and precipitate 
out of solution as NaCl is insoluble in acetone, thereby excluding chloride from 
participating in any potential secondary reactions. However, alternative to inclusion 
of the Finkelstein exchange step, an increase in temperature from RT to reflux 
conditions is sufficient for halide displacement and alkylation by thiolate to occur.  
3.3 Synthesis of Cep-glucose: Reaction schemes and spectral verification 
3.3.1 Cep-glucose synthesis scheme 
All solvents were purchased from Fisher Scientific, 4-methoxybenzyl-3-
chloromethyl-7-(2-phenylacetamido)-3-cephem-4-carboxylate was purchased from 










(400 mg, 0.200 mmol, 1 eq) was dissolved in 15 mL of acetone and 1-thio-β-D-
glucose (sodium salt, 132 mg, 0.6 mmol, 3 eq) was added to the reaction flask and the 
resulting suspension stirred at reflux for 4 h. The reaction mixture was cooled to room 
temperature and the solvent removed in vacuo to yield an orange oil. The crude 
mixture was dissolved in dichloromethane (10 mL) and washed with water (10 mL). 
The aqueous layer was extracted twice with dichloromethane (15 mL) and the 
combined organic extracts were dried over MgSO4. The solvent was evaporated in 




0.29) (Fig 3.5) were purified on a silica column with dichlormethane-methanol (94:6) 
to yield 89 mg (0.14 mmol, 70%) and 38 mg (0.06 mmol, 30%) of products 1 and 2 
respectively and a total product yield of 24%. Noting this relatively low yield, 
inclusion of the Finkelstein step (Fig 3.4) in an alternate lower-temperature synthesis 
can improve the yield. 
 
For spectral verification data of Compounds 1 and 2, please see Appendix I (1H 
NMR, 13C NMR, COSY, IR, MS). 
 
 
Figure 3.6. Synthesis of Cep-glucose (Compound 3) from PMB-Cep-glucose (Compound 1). 
 
 
In a 1-dram vial, dried 1 (35 mg, 0.052 mmol) was dissolved in 1 mL of DCM and a 
Teflon coated stir bar was added. The solution was cooled to 0 °C in an ice bath 
before adding 2 mL of a 5:1 v/v TFA:anisole solution. After stirring for 1 h at 0 °C, 
the vial was taken from the ice bath and the solvent removed in vacuo. To remove 
anisole as well as deprotection byproducts, the residue was dispersed in 3.5 mL cold 
Et2O and then centrifuged at approximately 6000 rpm in a benchtop IEC clinical 
centrifuge for 10 min. The supernatant was decanted and the solid residue then 




process repeated an additional three times. Residual Et2O was removed from the 
resulting white solid in vacuo to yield cep-glucose, 3, (22 mg, 0.042 mmol, 81%) as 
an off-white powder (Figure 3.6). The 1H-NMR shows and HPLC-MS support > 90 
% product purity, however some NMR invisible trifluoroacetate impurities are 
present as evidenced by trifluoroacetate complexed ions observed by mass 
spectrometry. Samples of 3 were stored in a -20 °C freezer until needed. 
For spectral verification data of Compound 3, please see Appendix II (1H NMR, 13C 
NMR, COSY, IR, MS). 
 
3.4 Cep-glucose substrate-enzyme kinetic studies with ESBL 








3.4.1. Lineweaver-Burke kinetic determination 
 
Varying concentrations of Cep-glucose (500 μM, 250 μM, 125 μM, 62.5 μM, 31.25 
μM) were incubated with 100 mU/ mL ESBL in triplicate (equating to an Etot of 3.77 
nM, assuming an average molecular weight of 35 kDa, and a specific activity of 5.87 
U/ mg as reported by AG Scientific). Optical absorbance (OD260 corresponding to the 
C-N bond in the β-lactam ring217) was recorded every seven seconds over 15 minutes 
to observe a decrease in OD indicative of enzymatic hydrolysis of the Cep-glucose 
substrate resulting in a ring-opened cleavage product. 
 
The graph above (Fig. 3.7) shows the Lineweaver-Burke plot of inverse velocity (s ∙ 
OD260
-1) against inverse concentration (μM-1). Velocity was computationally 
determined as the fastest change in OD260; absolute values of the negative change 
(decrease) in OD were used in this calculation to obtain a positive velocity. 
 
3.4.2 Mass spectroscopy on reaction products 
Methods. Cep-glucose (3) (262 μg, 500 nmol, 1 mM final concentration) (Fig 3.8) 
was dissolved in 0.5 mL 0.1 M phosphate buffer (pH 6.5). ESBL (1 U/ mL final 
concentration) was then added and the reaction incubated at 25 °C. At 1 h and 16 h, a 
150 µL aliquot was removed and purified through an Amicon Ultra centrifugal filter 
(regenerated cellulose, 3000 MWCO) in a benchtop centrifuge at 14,000 RCF for 15 





Results. LC-MS analysis of the reaction between Cep-glucose and ESBL revealed the 
presence of a ring-opened intermediate (4 in Fig 3.8), both confirming Cep-glucose’s 
function as a substrate for ESBL and thio-glucose as a poor leaving group. The 
following study was initially performed to confirm release of thio-glucose following 
ESBL-mediated ring opening. Though MS confirmed the presence of a weak signal 
indicative of thio-glucose, it also revealed the appearance of a strong signal 
corresponding to the mass of the ring opened intermediate with thio-glucose still 
attached, and, importantly, the disappearance of the initial Cep-glucose peak. Details 
of the experiments are described below. 
 
Interestingly, though spontaneous elimination of thio-glucose appeared to produce 
minimal signal of the product in the initial observations, the presence of Ellman’s 
reagent (DTNB) appeared to facilitate higher levels of thio-glucose release, as 
evidenced by DTNB capture to produce a mixed disulfide. (Please note: Further 
experimental methods and LC-MS analysis detailing the elimination behavior of 
thioglucose and its capture in the presence of Ellman’s reagent to produce the mixed 






Figure 3.8. Biochemical schematic representing ESBL cleavage, formation of the ring-opened 
intermediate, and spontaneous release of thioglucose. 
 
 
The chromatogram is similar for both the t = 1 h and 16 h samples, both showing two 
peaks with retention times 7.28 and 7.78 (Figs 3.9a and 3.10a) with a notable absence 
of any peak at 8.06 min which was previously assigned to cep-glucose (3) (See 
Appendix III, Fig A.3.3). The mass spectra for both the 7.28 and 7.78 min peaks give 
only one mass corresponding to the ring opened intermediate (4), appearing as [4 – 
H]- with calculated m/z 543.1113. The two different retention times and identical 
masses are consistent with two isomers of 4.  
 
Free thioglucose is invisible by UV so is not observed in the chromatogram. 
However, upon analysis of the solvent front for the 1 h sample, a very weak signal 




The other product of thioglucose elimination, 5, was not observed, likely due to its 
inherent instability. Similar results were obtained when the same experiment was run 
in 0.1 M phosphate buffer adjusted to pH 8.0.  
 
 
Figures 3.9a-d. LC-MS analysis of the reaction between cep-glucose and ESBL at t = 1h. a) 
Chromatogram showing two peaks at 7.28 min and 7.78 min. b) Mass spectrum corresponding to 
solvent front showing a very weak signal corresponding to thioglucose. c) Mass spectrum 
corresponding to the 7.28 min chromatogram peak showing only the ring opened intermediate 4. d) 







[thioglucose - H]- 
Calculated Mass: 195.0333 
[4 - H]- 
Calculated Mass: 543.1113 
[4 - H]- 





Figures 3.10a-d. LC-MS analysis of the reaction between cep-glucose and ESBL at t = 16h. a) 
Chromatogram showing two peaks at 7.27 min and 7.77 min. b) Mass spectrum corresponding to the 
7.28 min chromatogram peak showing only the ring opened intermediate 4. d) Mass spectrum 
corresponding to the 7.78 min chromatogram peak showing only the ring opened intermediate 4. 
 
3.4.3. Functional specificity studies. 
Methods. (For detailed scheme of colorimetric chemical readout please see section 
4.3.2.) In a 96-well standard clear microplate, two-fold dilutions of Cep-glucose 
substrate (625 μM to 39.0625 μM) and 250 μM DTNB (final concentrations) were 
diluted into 100 μL of 0.1 M PB (pH = 6.5). To each triplicate, either 200 μU/ mL of 
TEM-1 or ESBL was added, and optical absorbance (OD412) was measured every 30 




[4 - H]- 
Calculated Mass: 543.1113 
[4 - H]- 




Specificity of substrate for ESBL. Kinetic studies using Ellman’s reagent as a readout 
for thio-glucose release were performed to examine the cleavage of Cep-glucose as a 
substrate of different β-lactamase enzymes both classic, non-ESBL and ESBL. From 
the data shown, Cep-glucose is only cleaved by the enzyme blend containing ESBL 
(Fig. 3.12), and not by purified TEM-1 (Fig. 3.11), a non-ESBL classical β-lactamase. 




Figure 3.11. The Cep-glucose substrate is not cleaved by TEM-1, a non-ESBL. Varying concentrations 
of Cep-glucose substrate are diluted into 0.1 M PB (pH = 6.5) containing 250 μM DTNB. TEM-1 
narrow spectrum beta-lactamase (final concentration 200 μU/ mL) is added just prior to reading using 
an absorbance plate reader. Absorbance change at 412 nm is monitored every 30 seconds over the 
course of 45 minutes to measure generation of TNB production resulting from thio-glucose released 
upon substrate cleavage. No discernable change is observed for any concentration tested. (Note the y-






Figure 3.12. The Cep-glucose substrate is cleaved by the commercial ESBL blend. Varying 
concentrations of Cep-glucose substrate are diluted into 0.1 M PB (pH = 6.5) containing 250 μM 
DTNB. ESBL enzyme (final concentration 200 μU/ mL) is added just prior to reading using an 
absorbance plate reader. Absorbance change at 412 nm is monitored every 30 seconds over the course 
of 45 minutes to measure generation of TNB production resulting from thio-glucose released upon 
substrate cleavage. Increasing signals are observed with higher concentrations of cep-glucose substrate 
in a dose-response manner, indicating that cep-glucose is an ESBL substrate. 
3.5. Synthesis schemes of SERS-active reporters 
3.5.1. Cep-pNTP 
Cep-pNTP full IUPAC name: 7-(2-phenylacetamido)-3-[(4-nitrophenyl)thiomethyl]-
3-cephem-4-carboxylic acid. 
 
Synthesis of Cep-pNTP was performed using exactly the same procedure as Cep-




nitrothiophenol (pNTP, purchased from Sigma Aldrich). (For details, please see 
synthesis of Cep-glucose in previous section 3.3.) 
 
Figure 3.13. Plate reader absorbance kinetics monitoring Ellman’s reagent as a function of time to 
verify the release of pNTP from Cep-pNTP in the presence of ESBL and TEM-1. 250 μM cep-pNTP 
with equimolar DTNB is prepared in 0.1 M PB (pH = 6.5) to which varying unit concentrations of 
either ESBL or TEM-1 are added and absorbance at 412 nm is monitored every 30 seconds over one 
hour. A signal increase is only observed at 100 mU/ mL TEM-1 whereas 10 mU/ mL ESBL produces a 
much higher absorbance signal. The comparatively lower activity of TEM-1 on Cep-pNTP and higher 
cleavage activity by ESBL indicate Cep-pNTP is more specific to ESBL than TEM-1. (Note the 
difference in y-axis scales.) 
 
Functional verification & specificity of Cep-pNTP. Similarly to previous experiments 
in Chapter 4 with Cep-glucose, the liberation of a free thiol by hydrolysis of the beta-
lactam ring should yield a reactive residue detectable by Ellman’s reagent to produce 
a mixed disulfide and a colored TNB molecule whose absorbance peak can be 
measured at 412 nm. From this, we also observe that at equal unit concentrations, 
ESBL is much more effective at hydrolysis of Cep-pNTP than is TEM-1, whose 
signal is indistinguishable from the no enzyme control (PB pH 6.5 only) (Fig. 3.13). 




absorbance methods, we may substantiate that its readout activity by SERS rests on 
the basis of a hydrolytically functional molecule with a good leaving group. 
 
3.5.2. Cep-diNTP 
Cep-diNTP full IUPAC name: 7-β-thien-2-yl-acetamido-3-[(2,4-
dinitrophenyl)thiomethyl]-3-cephem-4-carboxylic acid 
 
Intermediate (Compound 2) (6R,7R)-7-amino-3-{[(2,4-dinitrophenyl)thio]methyl}-8-
oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) 
 
The synthesis of Cep-diNTP was based on the work of Quotadamo et al.218 The 
rationale in using the improved synthesis was to achieve higher yield without the 
deprotection requirement as reported in the publication.  
 
As shown in Figure 3.14, thiol (1,4-dinitrothiophenol, diNTP) was reacted with 7-
aminocephalosporanic acid (7-ACA) (Compound 1) in anhydrous acetonitrile 
(MeCN) in the presence of boron trifluoride to yield intermediate derivative 
Compound 2. Derivative 2 was then directly reacted with 2-(thiophen-2-yl)acetyl 






Figure 3.14. Synthesis scheme for Cep-diNTP. a) 1 (7-ACA, 1 equiv.), BF3 (3 equiv.), MeCN, r.t., 2h; 
b) 2-thienylacetyl chloride (1 equiv.), potassium trimethylsilanolate (2 equiv.), MeCN, r.t. 1 h, then 50 
°C, 2 h. 
 
 
Functional verification. Cep-diNTP was verified as a substrate of ESBL and non-
ESBL TEM-1 using a simple visual test. In 0.1 M PBS, 1 mM of purified Cep-diNTP 
substrate plus 250 μM DTNB was allowed to incubate with 10 U/ mL of ESBL or 
100 U/ mL non-ESBL TEM-1 enzyme. Within one minute, it was observable by 
visual inspection that both ESBL and TEM-1 produced a highly visible yellow color 
change whereas the no-enzyme control did not, confirming Cep-diNTP to be a 







Figure 3.15. Showing visually observable color change upon addition of TEM-1 or ESBL in the 
presence of Ellman’s reagent. All samples contain Cep-diNTP in 0.1 M PBS (pH 7.4). A no enzyme 
control (left) was compared to the addition of ESBL (middle) and TEM-1 (right); contrasting color 
changes were visible within 5 minutes. 
 
3.6 Conclusions 
Here we have detailed the synthesis of three new synthetic substrates and their design 
in functioning as different types of reporters of β-lactamase activity (see Chapters 4 
and 5). We establish that the specificities can be fine-tuned to a degree in terms of 
specificity to β-lactamase thereby distinguishing different evolutions of the enzyme. 
We also characterize the reaction products spectrally (H-NMR, C-NMR, MS, IR) to 
verify their structure, and determine enzyme kinetics through direct optical 
measurement. Finally, we also establish the presence of an intermediate of Cep-
glucose that persists after ring opening, and show its expulsion behavior is modified 
in the presence of DTNB. 
 
3.6.1 Future work: Establishing chemistries for easier, higher yield production 
of more detection substrates with tuned specificity. 
We utilize boron trifluoride in efforts to synthesize our Cep-diNTP substrate with a 




production of more detection substrates with different reporter moieties as well as 
different amide side chain determined specificities would be of high utility, especially 
in looking toward parallelization of array-format testing, or further multiplexing 
perhaps in a single or few samples. 
 
3.6.2 Future work: Oxidation of the Cephem starting material. 
Established procedures in the literature for the oxidation of the PMB-Cep-Cl starting 
material (either single or double) have shown increased stability15 and higher yield of 
the Δ2-Δ3 isomer that allows reporter release
219 (shown in the schematic). Future work 
on our current substrates could be to modify the starting materials to study their 
stability behavior and synthetic yields, as outlined by Scheme 3.2.3 below. 
 
 
Figure 3.16. (Synthetic plan) Oxidation of the starting material with the use of mCPBA; a) mCPBA, 
DCM, 0°C 1 h, r.t. 4 h; b) mCPBA, DCM, 0°C 30 min, r.t. overnight. 1 is produced from (a) only, 2 




Chapter 4: Cep-glucose, a trimodal detection substrate 
4.1 Introduction 
Bacterial resistance to β-lactam antibiotics continues to grow as their misadministration 
presents evolutionary pressure that drives bacteria to develop improved resistance 
enzymes. Known as extended-spectrum β-lactamases (ESBLs), these are capable of 
hydrolyzing advanced β-lactam antibiotics such as third- and fourth-generation 
cephalosporins. Phenotypic detection substrates can be used to rapidly identify a 
cultured patient sample within minutes prior to confirmation by more exhaustive but 
slower means, critically aiding in the antibiotic stewardship essential in maintaining 
the effectiveness of not only the cephalosporins but indirectly also the carbapenems, 
our last-resort β-lactams. To enhance the phenotypic detection arsenal, we have 
designed an ESBL detection substrate that releases a glucose molecule upon β-
lactamase cleavage.  Because many forms of detection for glucose exist, the substrate 
enables ESBL quantification via three modalities commonly found in the clinical 
laboratory: optical absorbance, for use with the most common microbiology platforms; 
fluorescence, for enhanced sensitivity; and electrochemistry, which offers the potential 
for integration into a handheld platform similar to a personal glucometer. 
 
As fluorescence measurement is generally accepted to have higher sensitivities than 
chromogens, which rely on absorbance spectrophotometry, the development of 
fluorogenic ESBL substrates has expanded the phenotypic detection repertoire with 




designed to release well-characterized coumarins upon specific cleavage by advanced 
ESBLs including metallo-β-lactamases (MBLs), an improvement on substrates unable 
to distinguish β-lactamases with extended-spectrum profiles from narrow-spectrum β-
lactamases.21  Yet, as previously described methodologies require the specialization 
of a central microbiology lab facility, resistance testing away from equipped central 
labs, such as in disadvantaged regions, remains an underserved goal. Electrochemical 
readouts of a redox-active reporter have the potential to meet this paradigm, as 
demonstrated by the handheld personal glucose meter (PGM). Amperometric 
measurements of hydrolyzed Nitrocefin have also been reported in the literature, with 
the aim toward rapid detection of ESBL activity using disposable screen-printed 
sensors with small sample volumes to enable robust, field-portable instrumentation.26 
The description of multiple methods for resistance readout is promising as a multi-
pronged approach to AMR detection, yet, each of these testing methods requires 
specific substrates, with each their own optimal readout modality. A single ESBL 
substrate possessing the versatility to enable different aforementioned readout 
techniques would democratize AMR testing access, as standard laboratories tend to 
have equipment for optical absorbance measurement, and more specialized, central 
laboratories possess fluorescence enabled equipment for sensitive detection (e.g., 
MicroScan Walkaway). Furthermore, though amperometric AMR detection is 
uncommon, establishing this methodology holds great promise toward the development 






Toward the accommodation of a wide scope of previously described detection 
methodologies, we have developed a new cephalosporin-derived detection substrate 
(Cep-glucose) capable of multimodal detection by colorimetric, fluorescence, and 
electrochemical means. Key to this multimodal detection is the use of thio-glucose 
release as the detection method. Once liberated from the substrate, the reactive thiol 
moiety of this reporter molecule allows for the conceptualization of any thiol-sensitive 
chemistries into downstream detection. Further, as thio-glucose is a substrate for 
glucose oxidase (GOx), established electrochemical detection methods allow for the 
easy reimagination of PGMs into ESBL quantifying POC detection devices. These 
important features are further enhanced by the promise of lowered production costs as 
compared to commercially available substrates, thanks to the ease of synthesis through 
straightforward thiol chemistry for alkylation and production of Cep-glucose, making 
it potentially commercializable as a low-cost substrate.  Here we demonstrate the use 
of this new substrate for the phenotypic detection of ESBL activity with colorimetric, 
fluorescence, and electrochemical readout.  
 
Figure 4.1 Our Cep-glucose detection substrate releases glucose as a trimodal reporter of ESBL-
mediated resistance activity. The released thioglucose can act as a signaling molecule for downstream 




4.2 Materials and Methods 
4.2.1 Reagents and solutions. 
Phosphate buffer (PB; 0.1 M; pH = 6.5) and all solutions were prepared with Milli-Q 
18-MΩ water (Millipore purification system) and pH-adjusted with HCl. 4-
Methoxybenzyl-3-chloromethyl-7-(2-phenylacetamido)-3-cephem-4-carboxylate was 
purchased from TCI America. 1-Thio-β-D-glucose was purchased from Cayman 
Chemical Company. Stock solutions of 50 mM Cep-glucose were prepared by 
dissolving the purified product in dimethylsulfoxide (DMSO) and aliquots were stored 
at -20 °C. Working dilutions were prepared by dissolving the stock solution in PB. 
TEM-1 β-lactamase enzyme was purchased from ThermoFisher Scientific. Extended-
spectrum β-lactamase (ESBL) was purchased from AG Scientific (β-lactamase-BS), 
and has been tested to show hydrolytic activity against a broad range of β-lactam 
compounds including third, fourth, and fifth generation cephalosporins as well as 
carbapenems. Due to its reliable cleavage as determined by our enzyme kinetic 
characterization studies, this ESBL “blend” was used as a standard in this study, as 
specified ESBLs are not commercially available. 5,5’-Dithiobis-[2-nitrobenzoic acid] 
(DTNB, Ellman’s reagent) was purchased from Sigma-Aldrich and a 100 mM solution 
was always freshly prepared in MilliQ water and diluted into PB to a final working 






4.2.2 New ESBL detection substrate: Cep-glucose 
Briefly, Cep-glucose was prepared as follows: 4-methoxybenzyl-3-chloromethyl-7-
(2-phenylacetamido)-3-cephem-4-caboxylate (PMB-Cep-Cl) was dissolved in 
acetone and 1-thio-β-D-glucose was added to the reaction and allowed to stir at reflux 
for 4 hours. After solvent removal in vacuo, the aqueous layer was extracted with 
dichloromethane to yield the para-methoxybenzyl-protected Cep-glucose. 
Deprotection was performed using standard trifluoroacetic acid deprotection 
procedures to yield the Cep-glucose detection substrate.  Full characterization of the 
Cep-glucose is presented in the supporting information.  For ESBL detection 
experiments, Cep-glucose was prepared from frozen stocks less than six months old.  
Moderate degradation in performance for long-term storage and for storage at 4 °C 
are shown in Appendix IV. 
4.2.3 Apparatus. 
All electrochemical measurements were carried out on the Model 800B Series 
Electrochemical Detector (CH Instruments, Inc.) potentiostat interfaced to a PC 
system equipped with the CHI832B Electrochemical Analyzer version 9.02 software. 
Zensor TE100 (#ET077-40, EDAQ) screen-printed carbon paste electrodes 
possessing a Ag/AgCl reference electrode were used for replicates in cyclic 
voltammetric measurements (CV; scan rate of 100 mV s-1), which were performed at 
room temperature with a working volume of 100 μL. CV peak heights were 
determined using eL-Chem Viewer, a freeware package available online 
(www.lchem.cz/elchemviewer.htm).220 All spectral measurements (optical density, 




multiplate reader interfaced to a PC system equipped with the SoftMax Pro 7 
software. 
4.2.4 Colorimetric assay with Ellman’s reagent. 
Ellman’s reagent reacts with free thiols to form a colored product (absorbance peak at 
412 nm) and thus was used to detect the release of thio-glucose upon cleavage of our 
Cep-glu substrate. Measurements were carried out at room temperature in standard 
96-well microplates in a 100 μL volume, with each well containing 200 μM Ellman’s 
reagent and 250 μM Cep-glucose substrate in PB (pH = 6.5). 
4.2.5. Fluorimetric assay with Amplex red reagent. 
Each 100 μL volume of PB (pH 6.5) contained final concentrations of the following 
reagents: 10 μM Amplex Red, 0.5 U GOx, 100 μU HRP, and 250 μM Cep-glucose. 
Just prior to reading, experimental dilutions of ESBL or only PB were added in 10 μL 
volumes to 90 μL of the previously described solutions. Oxidation of Amplex Red to 
resorufin within experimental samples was measured at room temperature over the 
course of 60 minutes at 30 second intervals in standard 96-well flat bottom 
microplates using the kinetic fluorescent read setting on the microplate reader, with 
excitation at 530 nm and emission measurement at 590 nm. 
4.2.6 Electrochemical assay via HRP enzyme inhibition by thiols 
Electrochemical measurements were performed using carbon screen printed 
electrodes from Zensor (EDAQ). Experiments were performed in a 0.1 M phosphate 
buffer (pH 6.5) containing 0.5 M KCl to increase the stability of buffer solution 




mediator with 12 μM hydrogen peroxide. Each 100 μL reaction volume contained 1 
U HRP, which was added after a 15 minute incubation of various dilutions of ESBL 
with 500 μM of our Cep-glucose substrate and pipetted to mix prior to measurement. 
CVs were run under a potential range of -0.4 to 0.6 V, a 100 mV/s sweep rate, with a 
sampling rate of 0.01 V. All samples were run in triplicate using new identical 
sensors as each replicate. An inhibitor calibration curve with thio-glucose as the 
inhibitor was produced to relate the current to released thio-glucose upon substrate 
cleavage following incubation (Appendix V). 
 
4.3 Results and Discussion 
4.3.1. Synthesis, verification, and characterization of Cep-glucose detection 
substrate. 
The Cep-glucose molecule is presented in Scheme 4.1.  As the state of research on 
detection of glucose and hydrogen peroxide is mature and reliable, we employed a 
thiolated form of glucose, 1-thio-β-D-glucose (thio-glucose), as the signaling 
molecule that is released upon hydrolysis of the substrate by ESBL. Importantly, as 
thiol chemistry would allow for a simple, one-step synthesis methodology followed 
by well-established acid-mediated deprotection protocols, we incorporated the 
thiolate in SN2 displacement of the halogenated cephalosporin starting material, 
PMB-Cep-Cl. The starting material was selected based on prior synthesis 
methodology by van Berkel et al.,219 who produced fluorogenic substrates for the 




material, through the addition of specific side chains, can be generalized to producing 
detection substrates cleavable by ESBLs hydrolyzing later-generation (third and 
beyond) cephalosporins. As compared to Nitrocefin or CENTA, which are cleavable 
by enzymes that inactivate second-generation cephalosporins, our starting material 
has a benzyl group where CENTA and Nitrocefin have a thiophene, implying that our 
Cep-glucose molecule will be more selective. Following synthesis and purification, 
we verified the structure of our substrate through standard procedural analysis of 
spectral profiles to confirm the formation of a cephalosporin derivative covalently 
attached to thio-glucose (see: Appendix I). 
 
Following synthesis of the new Cep-glucose molecule, we examined the adduct’s 
activity as a biochemical substrate for ESBL. Cep-glucose was tested as a substrate 
for an ESBL blend as well as individual older-generation β-lactamase TEM-1, which 
are not considered as extended spectrum. The kinetic characterization of Cep-glucose 
hydrolysis (presented in the Supporting Information) was performed by continuously 
recording the absorbance variation at 260 nm, as described in previous literature.171  
Using the ESBL blend, I determined that the ESBL and Cep-glucose substrate have a 
Michaelis constant KM of 572.65 μM and a catalytic constant kcat of 43.9 s
-1, with 
catalytic efficiency kcat/ KM to be approximately 0.077 s
-1 μM-1 (Vmax = 0.1655 s
-1, 
MW estimated as 35 kDa). In contrast to more promiscuous substrates like CENTA 
and Nitrocefin that are cleavable by nearly all β-lactamases, the starting 
cephalosporin material is specific for ESBL and is thus not cleavable by narrow-






Figure 4.2 Schematic for the colorimetric detection of ESBL. ESBL cleavage of Cep-glucose detection 
substrate, ring opened intermediate, spontaneous release of thio-glucose and capture by DTNB 
resulting in production of a colored TNB molecule (yellow) measurable by absorbance colorimetry. 
 
We designed our detection substrate to enable colorimetric readout via absorbance 
spectrophotometry in order to align with standard procedures and equipment found in 
clinical laboratories. The CENTA substrate directly releases the colored molecule 5-
thio-2-nitrobenzoic acid (TNB) upon hydrolytic cleavage; similarly, we employed 
5,5'-dithio-bis-[2-nitrobenzoic acid] (DTNB, also known as “Ellman’s reagent”), a 
symmetric molecule composed of two TNB halves linked by a disulfide bond, in our 




electronic rearrangement allows for the release of the attached thio-glucose, which 
may then participate in reactions enabling downstream readout modalities (Fig 4.1). 
As Cep-glucose releases thio-glucose upon cleavage by ESBL, which readily reacts 
with DTNB via its thiolate moiety to break the disulfide bond, it produces a mixed 
disulfide and colored TNB. The corresponding absorbance peak shift due to the 
resultant TNB can be measured at 412 nm.11,221 
 
Figures 4.3.A&B. Colorimetric dose-response timecourse and endpoint detection of ESBL using the 
Cep-glucose substrate. A) Kinetic absorbance readout and B) endpoint signal quantification of DTNB 
production resulting from ESBL degradation of Cep-glucose yielding thio-glucose elimination and 
product capture. (Please note: error bars are plotted for experimental triplicates but are not visible due 





To examine the detection performance of Cep-glucose as a colorimetric ESBL reporter, 
we incubated 250 μM Cep-glucose and 250 μM DTNB with varying unit 
concentrations (10 mU/mL to 1 μU/mL) of ESBL in 100 μL of 0.1 M phosphate buffer 
(pH 6.5 at RT), and monitored the absorbance peak over the course of 60 minutes (Figs 
4.3.A&B). Relying on optical density readout, we were able to easily distinguish a 
concentration of 100 μU/mL from lower amounts. The limit of detection was calculated 
to be approximately 19 μU/mL ESBL (approximated to be 70 pM assuming an average 
enzyme molecular weight of 35 kDa and a specific activity of 5.87 U/mg as provided 
by the vendor), corresponding to three standard deviations above the background 
signal, or OD412 of 0.07. 
4.3.2 Fluorimetric detection. 
 
Figure 4.4. Schematic for the fluorimetric detection of ESBL. Released thio-glucose is a substrate for 
GOx,, and produces hydrogen peroxide in the presence of oxygen. HRP in solution may then use the 
produced hydrogen peroxide to oxidize Amplex red into resorufin, which is measurable by 





With the intent of achieving lower limits of detection, we investigated the 
incorporation of our Cep-glucose substrate in a biochemical scheme to allow for 
measurable fluorometric readout. To accomplish this, we utilized thio-glucose’s 
ability to serve as a substrate for glucose oxidase (GOx), producing 1-thio-β-D-
gluconic acid and H2O2222 (Fig 4.4). For our fluorogenic molecule, we chose N-acetyl-
3,7-dihydroxyphenoxazine (Amplex red) as it has been well-characterized as a stable 
and sensitive reporter of H2O2, producing highly fluorescent resorufin (excitation 
maximum at 563 nm, emission maximum at 587 nm) in an irreversible enzyme-
catalyzed oxidative reaction mediated by HRP.223 Various concentrations of ESBL (1 
μU/mL to 10 mU/mL) were incubated with 250 μM Cep-glucose substrate and 10 μM 
Amplex red in the presence of 0.5 U GOx and 100 μU HRP in a 100 μL volume of 
0.1 M PB (pH 6.5) at room temperature, and the generation of an emission signal was 
continuously recorded at 590 nm with excitation at 530 nm over the course of one 
hour (Figs 4.5.A&B).  With the fluorometric assay, we estimate the limit of detection 
to be 0.98 μU/mL ESBL, which generates a signal that is larger than three standard 
deviations above the background signal.  Though the fluorometric read-out provides 
higher sensitivity than the colorimetric read-out, one aspect of the assay design 
prevents the difference from being much greater.  HRP, which catalyzes the 














Figs. 4.5.A&B. Fluorimetric dose-response timecourse and endpoint detection of ESBL using the Cep-
glucose substrate. A) Kinetic fluorescence readout and B) endpoint signal quantification of the 
oxidation of Amplex red into resorufin from released thio-glucose, degraded into byproducts including 
hydrogen peroxide by GOx. (Please note: error bars are plotted for experimental triplicates but are not 





4.3.3 Electrochemical detection by sulfide inhibition. 
Figure 4.6. Assay scheme for HRP-inhibitory electrochemical detection. Released thio-glucose is also 
a reactive free thiol that inhibits HRP activity, thereby decreasing redox activity that can be monitored 
by electroanalytical methods. 
 
Previous reporting of ESBL-producing E. coli strains through the amperometric 
detection of Nitrocefin cleavage,26 and methods of non-glucose target detection 
through engineered glucose generation schemes led us to explore Cep-glucose’s 
potential in expanding ESBL detection beyond the central lab by utilizing 
electrochemical methods. Though thio-glucose generated from Cep-glucose cleavage 
can in theory serve as a source of electrochemically active H2O2, we found that 
employing the sulfide detection scheme based on the sulfide inhibition of HRP 
previously described by Savizi et al. provided an electrochemical method with better 
performance (Fig 4.6).224 This scheme utilizes the inhibitory effect of thiols on HRP 
to decrease its participation in a redox cycling scheme that produces current via a 
hydroquinone (HQ) mediator. We expect that the release of thio-glucose from the 




and sought to demonstrate a dose-dependent current decrease with respect to ESBL. 
Varying amounts of ESBL were incubated for 15 minutes under identical conditions 
and HRP was added just prior to cyclic voltammetry measurement (time points up to 
60 minutes were tested, however no improvement in detection sensitivity was 
observed).  The depth of the oxidation peak was measured (Figs. 4.7.A&B), showing 
a decrease in oxidation current for increasing concentrations of ESBL.  A limit of 
detection of approximately 66 μU/mL was calculated (3σ above background). We 
produced a calibration curve measuring varying known amounts of thio-glucose 
(Appendix V). Back calculations using this calibration curve  indicate an estimated 







Figures 4.7.A&B. Electrochemical detection of ESBL using Cep-glucose substrate. A) Representative 
CVs showing inhibition peaks for varying concentrations of ESBL. As the potentiostat cycles through 
the set voltage limits a negative current peak corresponding to greatest thiol inhibition of redox activity 











4.3.4 Electrochemical detection of ESBL using Cep-glucose in a 
commercially available personal glucose monitor (PGM) 
Methods. The Cep-glucose detection substrate was prepared from a 19.5 mM stock in 
deuterated DMSO, diluted into 0.1 M phosphate buffer (pH = 8.5) to a final 
concentration of 3 mM. 1 µL of a 1 KU/ mL stock of the ESBL blend (AG Scientific) 
was added to 24 µL of the 3 mM Cep-glucose solution (final concentration 40 U/ mL 
ESBL) and allowed to incubate at 25ºC for 5 minutes. From this, a 2 µL aliquot was 
taken and pipetted onto a square of Parafilm®, a generic glucose oxidase based test 
strip (TruePoint, OK Biotech) was inserted into a OneTouch® Ultra2® blood glucose 
monitor (PGM) adjusted to calibration setting 49 (as directed on the TruePoint box), 
and the reservoir tip was touched to the aliquot allowing the sample to wick up into 
the test strip and held in place until a reading was displayed on the PGM. This 
process was repeated for the thio-glucose calibration control and the no ESBL 
negative control. The experiment was also performed for the following pH ranges: 
9.0, 9.5, 10.0, 10.5, 11.0, 11.5. 
 
Results. All pH values tested gave consistent results similar to pH 8.5 (but contributed 
to greater error range ± 5 mg/ dL) for the ESBL-positive experimental condition, with 
no ESBL registering in the PGM as “ERROR 4” or “low glucose”, and with the 
addition of 40 U/ mL ESBL registering just above the 20 mg/ dL displayed limit of 
detection. The 2.5 mM thio-glucose positive calibration control (used to compare the 




had consistently lower readings than what would be expected from an equimolar 








2.5 mM thio-glucose 35 ± 2 mg/ dL 2 mM 
40 U/mL ESBL 
3 mM Cep-glucose 
25 ± 3 mg/dL  1.5 mM 
No ESBL 
3 mM Cep-glucose 
 “low glucose, below 20 mg/ 
dL” (“ERROR 4” displayed) 
< 1 mM 
 
Table 4.1. Experimental and control results of PGM detection of ESBL with Cep-glucose. (Error for 
each experiment calculated from conditions performed in triplicate using new test strips.) 
 
Discussion. Thio-glucose released from the Cep-glucose substrate upon ESBL 
cleavage can accumulate in high enough concentrations to register a reading within 
the working range of a commercially available PGM. Though higher pH ranges do 
not appear to impact detection performance, if the entirety of the 3 mM Cep-glucose 
substrate is hydrolyzed to release the equivalent concentration of thio-glucose, the 
PGM would be expected to display a reading in the 50 mg/ dL range.  However, the 
consistently lower readings present a loss of approximately half the expected signal, 
indicating there is much room for improvement. Additionally, as free thio-glucose is 




(expected reading for 2.5 mM glucose is 35 mg/ dL), it may be an inherent property 
of thio-glucose as a poor substrate for glucose oxidase. Other strong considerations 
are the limiting rate of thio-glucose release from the ring-opened Cep-glucose 
intermediate, and if the released free thiol exerts any inhibitory effects in the 
TruePoint test strips that would impact electrochemical readout. 
 
4.3.5 Detection of ESBL-producing E. coli. 
SHV-4 ESBL-producing E. coli (strain J53-2 pUD21, ATCC product number BAA-
200) were initially streaked onto tryptic soy agar (Difco) plates containing 10 µg/mL 
ceftazidime as a selection agent and allowed to incubate overnight at 37 ºC to produce 
single colonies. From this, one colony was selected and allowed to grow overnight 
(16 hours, shaking at 37 ºC) in liquid tryptic soy broth (10 mL volume) containing 10 
µg/mL ceftazidime. CFU dilutions were prepared directly in PBS from the turbid 
culture. In a 96-well microplate, various conditions were prepared in 100 µL total 
volume of 0.1 M PBS (pH = 7.4): bacteria only, bacteria with 250 µM Ellman’s 
reagent, and ten-fold dilutions of bacteria (including a no bacteria control) with 250 
µM Cep-glucose detection substrate and 250 µM Ellman’s reagent. Samples were 
incubated in the microplate at 25 ºC and absorbance measurements at 412 nm were 




Figure 4.8. Colorimetric signal change for Cep-glucose with cultured E. coli that produces SHV-4 
ESBL. As compared to 0 CFUs (used as background subtraction), 107 CFUs with Cep-glucose and 
Ellman’s reagent generated an easily measurable signal. 107 CFUs with and without Ellman’s reagent 
(no Cep-glucose) were also included as negative controls. (Error bars were calculated from triplicates; 
experiment was reproducible.) 
 
Results. Within two hours of direct incubation of 107 CFUs E. coli with the Cep-
glucose detection substrate and DTNB, an increase in absorbance readout was 
observed as compared to the no Cep-glucose + DTNB control included to calibrate 
for any background chromogenicity (i.e., thiolates arising as metabolic byproducts); 
additionally, an increase in absorbance signal was observed after four hours. No 
discernable absorbance readout was observed for any lower CFU dilutions (Fig 4.8). 
 
Discussion. The signal magnitude for 107 CFUs after 2 hours is similar to the signal 




unclear how the onset of observable ESBL activity with live cells compares with our 
previous experiments using the commercial ESBL enzyme blend. Considerations to 
take into account are the Cep-glucose substrate’s diffusion behavior across the outer 
membrane into the periplasmic space where β-lactamases are localized. On a 
chemical level, this behavior may be impacted by Cep-glucose’s possession of many 
more hydroxyl groups as compared to previously established chromogenic substrates. 
Furthermore, the two-step disulfide exchange with DTNB to produce color may 
require diffusion of the TNB chromogen or released thio-glucose back out of the cell 
to contribute to readout. Exploration of sample preparation steps to include lysis by 
either chemical (detergents) or mechanical (sonication) means could help elucidate 
methods for improving detection performance at lower CFUs. 
4.4 Conclusion 
In this study we have shown that our new detection substrate Cep-glucose can enable 
three different readout modalities (colorimetric, fluorimetric, amperometric) for the 
detection of varying levels of ESBL spanning at least three orders of magnitude. Our 
colorimetric detection scheme using Ellman’s reagent allows for use of common 
absorbance spectrophotometry techniques. Our fluorescence detection scheme using 
Amplex red, despite greater assay complexity, provided lower limits of detection for 
greater sensitivity. Additionally, we engineered an amperometric means of detection to 




4.4.1. Future work: Optimizing HRP activity. 
Protein engineering of the HRP enzyme to be less susceptible to inhibition by thiols 
could provide a more robust enzyme for more efficient oxidation of Amplex red to 
resorufin and thus increase the sensitivities measured by fluorimetric readout. 
Alternatively, development of a synthetic protocol to achieve Cep-glucose adduct by 
way of an oxygen moiety in place of the sulfur as the C-3 position alkyl halide could 
produce a normal glucose molecule that undergoes more efficient oxidation by GOx, 
as well as eliminating the release of HRP-inhibitory thiols into solution, thereby 
resulting in an overall improvement in assay performance. 
 
4.4.2 Future work. Detection using commercial personal glucose meter. 
Optimization studies of either the assay (to increase release of thio-glucose from the 
Cep-glucose ring open intermediate through studies in buffer elements that may 
increase concerted expulsion of the leaving group) or the electrochemical detector 
(“hacked” glucometer for lower limits of detection) could result in sensitivities 




Chapter 5:  Cep-pNTP and Cep-diNTP, SERS-active reporters 
 
5.1 Introduction 
Previously we have described one detection substrate capable of reporting ESBL 
activity. However, given the various classes of β-lactamase as well as the ever-
expanding sub-classes as new permutations appear, it would be of great advantage to 
have a collection of reporter substrates corresponding to various β-lactamases from 
classical non-ESBL types to ESBL types, metallo-β-lactamases, and carbapenemases. 
Even more advantageous would be the capability of assaying for these different 
resistance enzyme evolutions in a single sample with a single measurement. Cep-
glucose and the currently developed chromogenic substrates (Nitrocefin, etc.) are 
unable to do this; however, as Raman spectroscopy is capable of single-sample 
multiplexing due to its narrow band optical properties, creation of a suite of detection 
substrates that release Raman-active reporter molecules—each with a unique optical 
fingerprint—would provide a resistance detection toolkit of immense benefit. 
Moreover, our use of sulfur/ thiol chemistry for the assembly and disassembly of our 
reporter molecule is compatible with surface-enhanced Raman spectroscopy (SERS), 
which utilizes metal nanostructures for signal enhancement. Thus, we investigated the 
synthesis of new ESBL sensing molecules for use with SERS. 
 
Here we will overview a basic explanation of the physics behind the theory of Raman 
scattering, its enhancement on appropriate nanometal surfaces, and how this allows 




5.1.1. Raman spectroscopy.  
Photons from incident light can interact with a molecule in different ways. The vast 
majority of interaction is in the form of an elastic scattering event, in which the 
molecule absorbs the energy, is raised to a virtual state (a temporarily stable 
vibrational mode), and emits the energy with no net change, falling back to its ground 
state in what is known as Rayleigh scattering. In a much rarer phenomenon, the 
excited molecule may fall back to a vibrational (real phonon) state higher than its 
ground state, emitting energy that is less than that of the incoming photon; this is 
known as Stokes shifted Raman scattering. In yet an even rarer third phenomenon, if 
the molecule is already in a vibrational energy (excited phonon) state when it is 
excited by another incident photon to a virtual energy state, it releases more energy 
than that of the incident photon in relaxing back to its ground state, a behavior known 
as anti-Stokes Raman scattering. Because anti-Stokes scattering is so rare, typical 
Raman measurements are only performed using Stokes shifted light (Fig. 5.1). 
 
Raman scattering behavior is highly dependent on and unique to the molecule’s 
underlying arrangement, thereby giving it a spectral signature “fingerprint”. It is also 
independent of virtual energy state, only depending on wavenumber to describe its 







Figure 5.1. Jablonski diagram representing quantum energy transitions for Rayleigh and Raman 
scattering. 
 
Raman scattering can also use any frequency of light, only requiring a 
monochromatic source (laser). This gives it a key advantage over IR spectroscopy as 
it can employ a wide range from UV to IR. Still, shorter wavelengths are more 
conducive to higher Raman scattering intensity as the power of scattering is 
proportional the fourth exponent of the light’s frequency (power ∝ ν4). Raman 
scattering is typically performed in the mid-visible to IR range in order to mitigate 
interference by the inherent fluorescence of a molecule which is also more intense at 
shorter wavelengths, but also maintain the power afforded by shorter frequencies. 
Another important advantage of Raman spectroscopy is its narrow-band nature as 
compared to fluorescence methods: bleed-over due to spectral overlap is not as 
prominent in Raman as in fluorescence, which is ultimately conducive to greater 





The most effective identification of analytes using Raman spectroscopy is achieved 
with pure samples, or when the analyte’s spectral behavior is represented by the most 
dominant portion of the recorded spectral range (i.e., the analyte is a particularly 
Raman-active molecule). However, Raman by itself is not particularly sensitive for 
most applications. As Raman was initially confined to high purity concentration 
samples, the enhancement discovery from SERS increased the effectiveness of 
Raman spectroscopy as an analytical technique by many orders of magnitude. 
 
5.1.2 Surface enhancement. 
Surface enhancement is carried out through the use of noble metal nanostructures. In 
these materials the Raman signal is enhanced by many orders of magnitude.225–228 
This enhancement due to two phenomena known as surface plasmon resonance (SPR) 
and chemical effects, the former of which is responsible for the majority of 
enhancement effects.229–231 Research advancing the enhancement properties of SERS 
through the engineering of nanostructures has led to the attainment of detection and 
identification on the single molecule level.231–233 A phenomenon known as “localized 
surface plasmon resonance (LSPR)” enables the generation of SERS enhancement on 
the surfaces of metal nanostructures. LSPR occurs when the oscillations of free 
surface electrons (“plasmons”) replete on the surfaces of appropriately-sized 
nanostructures couples with the excitation wavelength of incident light that is on the 
same order as the oscillations, generating “resonance”. LSPR accounts for the vast 




enhancement factor (≤ 104) is attributed to chemical enhancement which arises from 
direct bond coordination with the metal surface. 
 
In the current work, silver nanoparticles (AgNPs) are used as SERS surface materials 
thanks to their high resonance as compared to other noble metals such as copper, 
nickel, platinum, and aluminum.234 (Note that due to their similar resonance 
characteristics, gold nanoparticles can just as easily be employed in these studies. 
Both gold and silver based nanoparticles with diameters smaller than 5 nm exhibit 
high surface enhancement properties. However, gold has better stability properties 
than silver, giving it a longer shelf life and greater commercial potential.) 
 









where a is the average molecular radius of the nanoparticle and d is the analyte’s 
distance from the metal nanostructure surface. As evidenced by the distance 
relationship in this equation, critical to the effectiveness of SERS is the proximity of 
the analyte to the metal nanostructure surface.235–237 The above equation describes the 
diminishment of enhancement effects as to the twelfth power of total distance a+d. 
As a result, adsorption of target analytes to the metal surface is an advantageous 
strategy for the effective detection of rarer species in a sample volume (low 




unitary nanometer scale (i.e., over 50% decrease in enhancement at 2 nm from the 
surface), infeasibilies arising in the detection of bulkier biomolecules in the 
nanometer range constrain SERS based detection to small molecules as the ideal 
substrate class due to their diminutive size range. 
 
Advantages of SERS as a bioanalytical technique. Compared with UV-vis absorption 
spectroscopy and infrared spectroscopy, SERS gives a fingerprint vibrational 
information of the adsorbates on the metal surfaces, and the added advantage of its 
enormous enhancement factor of up to 1014, which brings the limit of detection down 
to the level of single molecules.232,238,239 SERS is additionally suitable for aqueous 
environments thanks to the transparency of water that allows the use of laser light as 
in Raman spectroscopy. This makes SERS based detection ideal for our biological 
matrix based assays, or in idealized aqueous media containing buffer salts. Thanks to 
its increased sensitivity, surface enhancement makes Raman ultimately a more 
feasible means as an analytical technique, and can be considered on par with 
fluorescence spectroscopy but superior multiplexing density.232,240,241 SERS is 
additionally advantageous over fluorescence in its label-free nature as it directly 
detects a molecular fingerprint without any additional treatment necessary. In 
comparing SERS to other highly sensitive spectroscopic techniques such as mass 
spectrometry, especially when paired with chromatographic separation methods (LC, 
GC) which provides extremely high resolution, the advent of portable SERS has now 








The basis for our SERS multiplexing is the release of different SERS-active small 
molecule reporters from the cephalosporin-derived detection substrate upon 
interaction with β-lactamase. The SERS-active small molecules were chosen based on 
several characteristics: (1) their strong nucleophilicity as thiolates participating in Sn2 
displacement organic synthetic reactions to produce our detection substrates; (2) their 
possession of an aromatic nitro group which has a large scattering cross-section due 
to the symmetric nitro stretch; and (3) their possession of a released thiol moiety 
when released, aiding in reaction with the AgNP surface to form a thiolate 
adlayer.237,242,243 
 
We based our choice of para-nitrothiophenol (pNTP) as it is very well established in 
the literature as a SERS active molecule with good adsorption properties.244 
Additionally, the synthesis of a second detection substrate releasing 2,4-
dinitrothiophenol (diNTP) was also based on its successful detection as reported in 
the literature.245,246 
 
In order to confirm that the two SERS-active reporter molecules had spectra that were 
sufficiently narrow-band without indistinguishable overlap, SERS measurements 




As observed from these spectra, ratios will be compared between the distinguishing 
peaks as follow in Table 5.1. 
Figure 5.2. Comparative SERS spectral overlay of pNTP and diNTP to identify distinguishing peaks 
between the two reporter substrates (both at 10 μM). 
 
 
Table 5.1. Comparative signature peak ratios for pNTP and diNTP SERS-active reporters. Calculated 
ratios between identified peaks and count values to be used as an initial standard metric representative 






5.1.4. Schemes for ESBL and non-ESBL distinguishing substrates. 
Our detection substrates have been designed with different SERS-active molecules as 
leaving groups (via C-3 position alkylation) that serve as specific reporters 
corresponding to differing amide side chains (at the C-7 position amino group). The 
presence of the benzyl group on Cep-pNTP is designed to behave similarly to 
cephalosporin antibiotics that have a similar or identical side chain, which are often a 
feature of the second-generation cephalosporins (e.g., Cefaclor) and can thus be 
generalized to be indicative of resistance toward them. Figure 5.3 depicts preferential 
cleavage of Cep-pNTP by ESBL, thus liberating the pNTP thiolate, allowing it to 
participate as a SERS-active molecule. 
 
Figure 5.3. Cep-pNTP substrate which represents a second-generation cephalosporin is hydrolyzed by 





Under the same rationale as the detection substrate just described, Cep-diNTP was 
designed with a C-7 amide side chain possessing a thiophene group. The presence of 
this thiophene is found in many first-generation cephalosporins (e.g., Cefalotin), and 
is expected to be hydrolyzable by classical, non-ESBL enzymes such as TEM-1. In 
fact, Cep-diNTP is structurally identical to Nitrocefin, a substrate of TEM-1, with the 
exception of the sulfide moiety as the C-3 position alkyl halide. (Again, the purpose 
of attachment by the sulfur is to enable the release of the diNTP SERS-active reporter 
upon intramolecular rearrangement leading to halide expulsion, upon β-lactam 
cleavage.) As shown in Figure 5.4, the Cep-diNTP substrate is expected to be 
hydrolysable by both classical TEM-1 and ESBL thanks to its extended-spectrum of 
activity. 
 
Figure 5.4. Cep-diNTP substrate can be hydrolyzed by both a non-ESBL classical β-lactamase (TEM-





5.2.1 Absorbance colorimetry. 
Ellman’s reagent reacts with free thiols to form a colored product (absorbance peak at 
412 nm) and thus was used to detect the release of thio-glucose upon cleavage of our 
Cep-glu substrate. Measurements were carried out at room temperature in standard 
96-well microplates in a 100 μL volume, with each well containing 250 μM Ellman’s 
reagent and 250 μM of the Cep-pNTP or Cep-diNTP substrate in PB (pH = 6.5). 
5.2.2 Measurement by SERS 
SERS paper sensors printed with silver nanoparticles were purchased from Metrohm 
and cut into 5 mm x 5 mm squares prior to use. SERS measurements were performed 
using a portable Raman system consisting of a 785 nm diode laser (Innovative 
Photonic Solutions, Monmouth Junction, NJ), QE65000 Raman spectrometer (Ocean 
Optics, Dunedin, FL), and fiber optic probe (Integrated Photonic Solutions, 
Monmouth Junction, NJ). Laser power is set to approximately 15 mW. Each spectrum 
is collected using a 1 second CCD exposure for 3 accumulations (averaged). Spectra 
are averaged across 5 spots (in a configuration like the value 5 on a six-sided die). 
Data were analyzed in MATLAB using custom in-house code adapted from the 
literature.247 
5.2.3 Multiplex detection of ESBL and non-ESBL with SERS 
Samples consisted of 250 μM of each detection substrate (Cep-pNTP, Cep-diNTP) in 
100 μL 0.1 M PBS (pH = 7.4), to which either final concentrations of 10 mU/ mL 




incubate for 10 minutes, after which 2 μL volume aliquots of the sample were 
pipetted onto the sensor. After 15 minutes of air dry time, SERS measurements were 
made. 
 
Dose-response experiments were performed in the same way, except with 100 μM 
substrate in 0.1 M phosphate buffer (pH = 8.0) and an incubation time of 1 h, after 
which a 4 μL sample volume was pipetted onto the sensors, and given 25 minutes of 
dry time prior to measurement. 
5.3 Results 
5.3.1 Dose-response behavior of SERS-active reporter release. 
In our first step of directly establishing SERS-based detection, we first must observe 
that Cep-diNTP is also a cleavable substrate of ESBL. To do this, we incubate it with 
ESBL under the same conditions as previously described, and observe an increase in 
SERS signal while remaining conscious of baseline (no ESBL background) 
considerations. In Fig. 5.5, we can see that Cep-diNTP is a ready substrate for ESBL, 






Figure. 5.5. Cep-diNTP is cleaved by ESBL (10 mU/mL) and releases diNTP. Higher photon counts 
are observed in the presence of ESBL, indicative of the SERS activity resulting from diNTP binding to 
the SERS substrate surface; minimal signal is observed with Cep-diNTP alone. 
 
Using our Cep-pNTP substrate, we can observe a dose-response behavior as it 
produces spectra of greater peaks with increasing concentrations of ESBL, indicating 
the release of more pNTP reporter. The spectra display identifying peaks that are in 
accordance with the previously shown spectra of pNTP in solution (Fig. 5.2 overlay). 
We can easily visualize this dose-response behavior (Fig 5.6) through use of the 
diagnostic SERS peak at 1340 cm-1, which from Fig. 5.2., can be seen as the most 
prominent (strongest) to yield highest sensitivities when monitoring pNTP for ESBL 
detection. (NB: The strong 1340 cm-1 peak is shared by both diNTP and pNTP, only 




Therefore, subsequent single-sample multiplexing instead utilizes peaks that are 




Figure 5.6. Dose-response behavior of Cep-pNTP substrate with increasing amounts of ESBL 
concentration (0.01 mU/mL ESBL to 100 mU/mL in 10-fold dilutions). Data points represent spectral 
peaks at 1340 cm-1 and are normalized to the no ESBL control. (Please note: plots represent 
experiments performed in triplicate with error bars present but not seen due to their small values.) 
 
5.3.2 Comparative spectra for multiplex analysis. 
Here we introduce both substrates combined in solution to incubation with either no 
enzyme, ESBL, or TEM-1 (non-ESBL). Depicted in Figure 5.7, our three different 
samples represent cases where there is ESBL present, non-ESBL enzyme present, and 
no enzyme present. As expected, the ESBL is able to hydrolyze both Cep-diNTP and 







Figure 5.7. SERS can distinguish ESBL from non-ESBL TEM-1 through use of Cep-pNTP and Cep-
diNTP substrates. SERS-active reporters in combination give different spectral readouts corresponding 









Figure 5.8. SERS spectra from both substrates with ESBL. Plot [1] ESBL (10 mU/mL) incubated with 
0.25 mM of both substrates (Cep-pNTP, Cep-diNTP) in PB for 10 minutes. [2] is both substrates alone. 






Figure 5.9. SERS spectra from both substrates with TEM-1 non-ESBL. Plot [1] is 1 U/mL of TEM-1 
classical β-lactamase enzyme with 0.25 mM of both substrates (Cep-pNTP, Cep-diNTP) in PB for 10 
minutes. [2] is both substrates alone. These spectra are analyzed with those from Fig. 5.8 to 
demonstrate distinguishing ability. 
 
We then add classical β-lactamase TEM-1 (non-ESBL) to an equal molar mixture of 
both substrates (Cep-pNTP, Cep-diNTP). Here in Fig. 5.9, we observe a different 
spectral readout in comparison to the previous plot (Fig. 5.8). 
 
By calculating the ratios of the comparative signature peaks as outlined above in 
Table 5.1, we can distinguish the presence of ESBL versus TEM-1 in the full reaction 
that includes equal starting concentrations of Cep-pNTP and Cep-diNTP. Here we 
can observe the peak ratios to determine the relative presence of reporter 




calculated values in Table 5.2, we see the addition of TEM-1 into an equimolar 
substrate combination produces lower peak ratios (signatures of pNTP divided by 
diNTP), across all three diagnostic peaks at unique wavenumbers, indicating the 
greater presence of diNTP as the Cep-diNTP is preferentially hydrolyzed by the non-
ESBL. With the addition of ESBL, we observe peak ratios generally closer to the 
values obtained with equimolar diNTP and pNTP shown in Table 5.1, with the 
implication that ESBL cleaves both substrates while TEM-1 cleaves the Cep-diNTP 
substrate more efficiently. Further characterization by enzyme kinetic studies would 
help elucidate this behavior. 
 
 Peak ratios  
(photon counts of pNTP/diNTP) 
Wavenumbers 726:747 860:839 1088:1150 
TEM-1 1.390 0.9195 2.087 
ESBL 2.815 2.378 6.422 
 
Table 5.2. Ratiometric calculations of diagnostic peak heights corresponding to pNTP and diNTP 
reporters following enzymatic cleavage. Compared to ratios in Table 5.1, the lower ratios of samples 
containing TEM-1 seen here indicate increased hydrolytic activity on Cep-diNTP (due to a larger 
denominator); samples containing ESBL have a ratio more similar to that of Table 5.1, suggesting 
ESBL acts on both substrates with minimal preferential behavior. 
 
5.4. Conclusion 
Here we have shown SERS to be a viable methodology for the multiplex detection of 
different β-lactamase enzymes within the same sample using a single sensor. Future 




an attempt to better understand the ratiometric behavior of SERS reporters in 
multiplex detection of β-lactamase enzymes possessing different activity spectrums. 
 
In continuing toward the creation of a suite of SERS reporter substrates, we can begin 
by the inclusion of commercially available ESBL substrates (Fig. 5.10) such as 
CENTA, an established chromogenic substrate, or ceftriaxone, a third-generation 
antibiotic that also happens to have a releasable thiol moiety that is also SERS active. 
From here, we may continue to synthesize more reporter-releasing substrates with 
varying amide side chains to tune specificities to different families of β-lactamases. 
At this point, we would implement a more sophisticated processing strategy for signal 
analysis of resultant SERS spectra, such as principal component analysis (PCA), or 





Figure 5.10. Two commercially available substrates that may serve as SERS reporters. SERS-active 
groups are labeled in magenta. CENTA is a first-generation cephalosporin with the corresponding side 





Chapter 6:  Conclusion 
6.1: Summary of findings 
In the previous reports, we have established the chemical synthesis and 
characterization of detection substrates capable of reporting β-lactamase enzymatic 
activity. In this toolkit, we present Cep-glucose, a completely novel ESBL detection 
substrate, that releases glucose as a reporter that can be coupled into biochemical 
assay schemes enabling readout by three different modalities (absorbance 
colorimetry, fluorescence, electrochemical). We then elect the use of SERS as a 
readout modality with multiplexing capability, and detail the synthesis and behavior 
of two more previously undescribed detection substrates that can distinguish ESBL 
from non-ESBL in a single sample, single sensor format. Furthermore, we validate 
the great potential of our engineered assays by demonstrating successful performance 
with live bacterial cultures, as well as demonstrating drug resistance readout using 
unmodified store-bought personal glucose meters. 
 
6.2: Contributions to the field and potential impact 
6.2.1. Potential for direct impact on patient outcome 
As our work directly detects the resistance activity conferred by the most common 
survival strategy employed by microbes associated with nosocomial infection, it lays 
the foundation for direct testing of patient clinical samples. Especially important in 
the interrogation of a clinical sample is multiplex detection, as the same pathogen is 
likely to produce a variety of beta-lactamases; therefore, the multiplex strategy 




Though not directly addressed by this work as it also requires populational studies to 
assess accuracy rates, it is clear the application of our previously described assays to 
real clinical samples would yield results regarding bacterial susceptibility to 
cephalosporin treatment, directly informing the course of patient care, and therefore 
also health outcomes.  
6.2.2. Potential impacts on public health 
Antibiograms provide overall antimicrobial susceptibility profiles in order to serve as 
a treatment guide for regional hospital or healthcare systems. CLSI recommends the 
compilation of aggregate data at least annually with a minimum of 30 test isolates 
within the period analyzed. As our work aims to provide a diagnostic tool that is a 
rapid, post-culture test for resistance enzymes that is both inexpensive and can be 
performed in a standard lab, integration of our tool into the antibiogram workflow can 
speed compilation efforts by acting as an initial confirmatory test for clinical 
specimens regarding cephalosporin susceptibilities. This speed has the potential 
added benefit of facilitating more frequent antibiogram updates in order to more 
closely track cephalosporin resistance trends on the population scale especially as it 
pertains to this most commonly prescribed antibiotic class. Follow-up confirmatory 
tests can focus on any “hot spots” of resistance emergence to better allocate efforts in 
high-throughput susceptibility screenings for more efficient use of more resource-




6.2.3. Supporting higher accessibility to healthcare 
As our work has demonstrated resistance readout methodologies requiring simpler 
tools with lower technical expertise requirements than gold standard testing, we 
expect that it would make AST more commonplace. As optical plate readers are a 
standard unit of lab equipment, patient samples need not be shipped to central testing 
laboratories prior to days-long turnaround for results. Portable SERS instruments also 
brings additional multiplex capability to resistance testing outside of the central 
laboratory. If established as an AST methodology, even more isolated populations 
with the potential for bottlenecking of bacterial genetics can be profiled to trace the 
origins of resistance dissemination.  
 
Our electrochemical testing proof-of-concept lays the real potential for finer 
adaptation of our Cep-glucose based ESBL assay for use with highly portable and 
commercially available personal blood glucose monitors (PGMs) that have been FDA 
approved for home use, making AST as quick and readily available as hourly blood-
sugar testing for type 1 diabetics. Viability of PGMs as an AST method would follow 
a two-pronged approach: the further optimization assay conditions to maximize the 
release of glucose in our Cep-glucose scheme, and the customization of PGMs to 
have lower limits of detection for increased sensitivity.  
 
Overall, the methodologies described in this work aim to lower the barrier of access 
to AST by implementing less time and labor-intensive assay strategies aimed at 
detection of the most common bacterial resistance strategy to the most commonly 




6.3: Future work 
6.3.1. Studies with mock matrices 
Systematic testing the robustness of our assays in controlled matrices to include 
potential interferents (e.g., residual glucose, hydrogen peroxide, contaminating 
proteins, ions, reductants, oxidizers, etc.) would provide a first necessary step in 
adapting the assays for use in the clinic. 
6.3.2. Studies with live bacteria 
As all standard phenotypic detection methodologies are performed post-culture, our 
assays should be performed with various other strains of live bacteria from resistant 
isolates to confirm feasibility in clinical use. 
6.3.3. Studies with clinical human samples. 
Once the prior two future work goals are completed, robustness testing using real 
clinical samples from human patients on a population level would provide the 
necessary reliability data to determine precision, accuracy, etc. required prior to FDA 
approval. 
6.3.4. Furthering SERS based multiplex detection 
As discussed in Chapter 5, the synthesis of a suite of detection substrates each with 
unique SERS reporters (leaving group) that correspond to different cephalosporin 
generations (amide side chain) would provide an ultimate single-sample, single-
sensor screen for cephalosporin resistance. Additionally, development of multiplex 




software format to automate analysis for easier user interpretation. Ultimately, this 
would pair with a sample workflow that integrates patient sample application into a 
single-package device, thus providing a powerful tool for resistance analysis beyond 
the central laboratory. 
6.3.5. Ultra-convenient and pervasive resistance detection 
Similar to creation of a suite of SERS-active reporter substrates, side chain 
modifications could provide a suite of glucose-releasing ESBL detection substrates 
for detection using the PGM. Because of its high portability and FDA approval, PGM 
repurposing for AST holds a huge potential for the sensing of specific resistance 
mechanisms, in our case the hydrolytic activity of ESBL. Studies to compare different 
levels of resistance corresponding to MIC would be useful in validating PGM 
performance; accordingly, as PGMs have already been optimized to report 
quantifiable levels of glucose in blood, the amount of resistance activity can in theory 
be quantified from a given patient sample, particularly pertaining to cases of sepsis. 
Immobilization of glucose oxidase and catalase in collection tubes could provide a 
streamlined sample preparation strategy to reduce background glucose levels. In 
considering other sample types, new sample prep methods could be engineered, 
custom test strips be designed, and custom glucometers could be adapted for 
dedicated use in the clinic or bedside. In the hospital, attachment of a device 
containing the Cep-glucose substrate to standard tubing equipment could be a 
potential strategy to monitor for the presence of ESBL producing organisms. Overall, 
enabling drug resistance detection in PGMs holds immense potential for simple and 










Appendix 1. Verification spectra for PMB-Cep-glucose (Compound 1 and 2). 
Prepared by Dr. Shweta Ganapati, University of Maryland College Park (Chemistry 
& Biochemistry). 
Cephem 1: IR (ATR, cm-1): 3327(w, br), 2981 (s), 1776 (m), 1717 (m), 1669 (w), 1516 
(s), 1512 (m), 1454 (m), 1382 (m), 1248 (m), 1161 (m), 1030 (m), 907 (m), 823 (w), 
7569 (m), 730 (s).1H NMR (600 MHz, CDCl3): 7.44 (d, J =  8.9, 1H), 7.28 - 7.20 (m, 
7H), 6.83 (d, J = 8.6, 4H), 5.71 (dd, J = 4.7, 8.9, 1H), 5.17 (d, J = 11.7, 1H), 5.10 (d, J 
= 11.7, 1H), 4.97 (d, J = 9.9, 1H), 4.90 (d, J = 4.7, 1H), 4.28 (d, J = 13.7, 1H), 3.81 - 
3.72 (m, 5H), 3.56 – 3.27 (m, 12 H), 2.96 (d, J = 13.7, 1H). 13C NMR (150 MHz, 
CDCl3): δ 172.0, 164.8, 162.3, 160.2, 134.4, 131.0, 129.6, 129.0, 128.0, 127.5, 126.8, 
124.1, 114.3, 86.0, 79.8, 78.4, 72.8, 71.1, 68.6, 63.2, 59.7, 58.1, 55.5, 53.6, 43.5, 33.7, 
31.1, 26.4. High-Res MS (ESI): m/z 669.1554 ([M + Na]+), calculated for 
C30H34N2O10S2Na
+ 669.1553.  
Summary: The 1H NMR shows coupling between Ha 7.44 ppm (d, J = 8.9, 1H) and Hb 
5.71 ppm (dd, J = 4.7, 8.9, 1H), Hb 5.71 ppm (dd, J = 4.7, 8.9, 1H) and He 4.90 ppm 
(d, J = 4.7, 1H), Hc’ 5.17 ppm (d, J = 11.7, 1H) and Hc 5.10 ppm (d, J = 11.7, 1H), and 
Hf’ 4.28 ppm (d, J = 13.7, 1H) and Hf 2.96 ppm (d, J = 13.7, 1H), labeled in Figure 1. 
The splitting patterns of these peaks and their integrals are consistent with these 
assignments. Both systems, Hc’, Hc and Hf’, Hf have large coupling constants, 11.7 
Hz and 13.7 Hz, respectively, due to germinal coupling. All the correlations inferred 
from coupling constants in the 1H NMR spectrum are also observed in the COSY data 




4.97 ppm (d, J = 9.9, 1H) correlates to its vicinal proton (C2) on the thioglucose ring, 
and its coupling constant of 9.9 Hz indicates that the two protons are axial to each other. 
Accordingly, the anomeric configuration is β.    
 
 














Cephem 2: 1H NMR (600 MHz, CD3CN): 7.37 (d, J = 8.0, 1H), 7.34 – 7.25 (m, 7H), 
6.92 (d, J = 8.6, 2H), 6.28 (br s, 1H), 5.48 (br s, 1H), 5.42 (dd, J = 3.8, 8.0, 1H), 5.19 
(d, J = 3.8, 1H), 5.11 (s, 2H), 4.19 (d, J = 9.7, 1H), 3.78 (s, 3H), 3.74 – 3.02 (m, 14 H).   
13C NMR (150 MHz, CD3CN): δ 172.2, 168.5, 165.6, 161.0, 136.4, 131.6, 131.4, 131.1, 
130.4, 130.2, 129.6, 128.5, 127.9, 122.0, 119.4, 118.4, 115.0, 84.9, 81.3, 79.3, 79.2, 
73.6, 71.3, 68.5 62.8, 61.8, 56.0, 54.2, 50.4, 43.3, 35.7. 
Summary: All NMR data for cephem 2 was collected in CD3CN instead of CDCl3 as 
the peaks were better resolved in CD3CN. The 
1H NMR shows coupling between Ha 
7.37 ppm (d, J = 8.0, 1H) and Hd 5.42 ppm (dd, J = 3.8, 8.0, 1H), and Hd 5.42 ppm (dd, 
J = 3.8, 8.0, 1H) and He 5.19 ppm (d, J = 3.8, 1H), labeled in Figure 4. The splitting 
patterns of these peaks and their integrals are consistent with these assignments. These 
correlations are also observed in the COSY data shown in Figure 6. The COSY data 
also shows that protons Hb 6.28 ppm (br s, 1H), and Hc 5.48 ppm (br s, 1H), are coupled 
to each other, Figures 6 and 7. Interestingly, these protons are broad singlets in the 1H 
NMR spectrum, presumably with very small coupling constants. These protons are 
connected through 3 carbon atoms and show long range W-coupling due to the 
conformation of the cephalosporin ring system. In cephem 2, protons Hf 5.11 ppm (s, 
2H) correspond to a sharp singlet which does not correlate with any other protons. This 
singlet peak is in contrast to protons in the same position in cephem 1, Hc’ 5.17 ppm (d, 
J = 11.7, 1H) and Hc 5.10 ppm (d, J = 11.7, 1H) which are diastereotopic. The 
correlation of anomeric proton Hg 4.19 ppm (d, J = 9.7, 1H) to its vicinal proton (C2) 
on the thioglucose ring is observed from the COSY data, Figure 6. Proton Hg in cephem 




the same position in cephem 1. However, their coupling constants with the 
corresponding vicinal protons on the thioglucose rings are comparable (9.7 Hz and 9.9 




























Figure A.1.7. COSY spectrum (600 MHz, CDCl3) recorded for 2 showing correlation 










Appendix 2. Verification spectra for Cep-glucose (Compound 3). 
Prepared by Dr. David Watts, University of Maryland College Park (Chemistry & 
Biochemistry). 
1H NMR (600 MHz, 22 oC, DMSO-d6), δ: 13.44 (bs, 1H), 9.08 (d, J = 8.3 Hz, 1H), 
7.33 – 7.25 (m, 4H), 7.22 (tt, J = 6.9, 1.8 Hz, 1H), 5.63 (dd, J = 8.3, 4.7 Hz, 1H), 5.06 
(d, J = 4.7 Hz, 1H), 4.19 (d, J = 9.7 Hz, 1H), 3.94 (d, J = 13.6 Hz, 1H), 3.76 (d, J = 
17.8 Hz, 1H), 3.66 (d, J = 11.9 Hz, 1H), 3.59 – 3.52 (m, 2H), 3.52 – 3.42 (m, 3H), 
3.17 – 3.08 (m, 2H), 3.08 – 3.01 (m, 1H), 3.00 – 2.94 (m, 1H). Glucose alcohol 
protons appear at 3 – 5.5 ppm but are too broad to integrate. 
 
HRMS, ESI (-): m/z 525.0150 ([3 - H]-), calculated for C22H25N2OS2
- 525.1007. 
 
Summary: 1H-NMR shows coupling between Ha 9.08 ppm (d, J = 8.3 Hz, 1H) and Hb 
5.63 ppm (dd, J = 8.3, 4.7 Hz, 1H), as well as Hb 5.63 ppm (dd, J = 8.3, 4.7 Hz, 1H) 
and He 5.06 ppm (d, J = 4.7 Hz, 1H), labeled in Figure A.2.1. These assignments are 
supported by COSY NMR (Fig A.2.3). Hf’ 3.94 ppm (d, J = 13.6 Hz, 1H) was assigned 
based on an identical J coupling value and similar chemical shift to the analogous 
proton in 1 while COSY data shows that the coupled geminal proton Hf is overlapping 
with other peaks at 3.46 ppm. Importantly, in the spectrum of 3, all the protons 
associated with the p-methoxy benzyl protecting group are missing while the lactam 
protons Hb and He are still present (Fig A.2.2) with similar J coupling and chemical 
shifts, suggesting the lactam remains intact. Additionally, the anomeric C-Hd proton 




of the glucose moiety is retained. Finally, the new carboxylic acid proton appears as a 
broad singlet at 13.44 ppm while the alcohol protons on the thio-glucose fragment 
appear as a very broad unintegrateable resonance (3 – 5.5 ppm), likely due to fast 
exchange with residual H2O. 
 


















Figure A.2.2. Comparison of the 3.5 – 6 ppm range in the 1H-NMR spectra of cep-
glucose, 3, (blue trace, 600 MHz, DMSO-d6) and PMB-cep-glucose, 1, (red trace, 600 
MHz, CDCl3). Of note is the absence of the protecting group methylene protons Hc 
and Hc’ and methoxy group OCH3 (3.73 ppm) in the spectrum of cep-glucose, 3, 

























































Appendix 3. LC-MS experimental data for PMB-Cep-glucose and Cep-glucose 





For all LC-MS experiments, an injection volume of 5 µL was used and the mobile 
phase consisted of 0.1% formic acid solution (A) and methanol (B). The separation 
was performed on an Agilent 1100 as follows: the concentration of solvent B started 
at 10 % from 0 to 2.0 min, linearly increased to 75 % at 7.0 min, increased to and 
kept at 100 % from 9.0 to 12.0 min, then decreased to and kept at 10 % from 13.0 to 
15.0 min. A reverse-phase Imtakt Cadenza-C18 column (2.0·50mm, particle size 3 
µm) was used, and the flow rate was set to 0.25 ml/min. Chromatograms were 
produced using a 190 – 400 nm UV detector. 
The HPLC was fed into a Jeol AccuTOF ESI mass spectrometer operating in negative 
mode with a needle voltage set to -2100 V and 250 °C vaporizing temperature. A 
spectral window of 150 – 800 m/z was monitored. 
 
LC-MS of PMB-cep-glucose (1): 
A sample of PMB-cep-glucose (1) (267 μg, 4 nmol, 2 mM final concentration) was 
dissolved in 0.2 mL MeOH and analyzed by LC-MS. Only one peak in the 
chromatogram was observed (Fig S*). The mass spectrum showed masses belonging 
to [1 – H]-, [1 + HCOO]-, [1 + COOCF3]
- (Fig S*). Formate comes from HPLC 




originating from the deprotected cep-glucose product (3) which had been analyzed 
prior to this sample on the same column. 
 









Figure A.3.2. Mass spectrum of the 9.56 min chromatogram peak showing PMB-cep-





















[1 – H]-, Calculated Mass: 
645.1582 
 










LC-MS of cep-glucose (3): 
A sample of cep-glucose (3) (157 μg, 300 nmol, 1 mM final concentration) dissolved 
in 0.15 mL 0.1 M phosphate buffer (pH 6.5) was analyzed by LC-MS. Only one peak 
in the chromatogram was observed with a retention time of 8.06 min (Fig A.3.3). The 
mass spectrum of this peak shows only one major species, belonging to [3 – H]- (Fig 
A.3.4). 
 






Figure A.3.4. Mass spectrum of the 8.06 min chromatogram peak showing cep-



























Using Ellman’s reagent to visualize thioglucose release by LC-MS: 
In order to visualize the release of thioglucose by LC-MS, Ellman’s reagent (dithio 
nitrobenzoic acid, DTNB) was used. DTNB absorbs in the UV region and therefore 
both the reagent itself and its derivatives are observed in the chromatogram. 
Secondly, due to the presence of a carboxylic acid moiety on both aryl rings, DTNB 
and its derivatives are easily ionized and observed in negative mode by ESI-MS.  
LC-MS analysis of cep-glucose (3) in the presence of Ellman’s Reagent: 
 
Cep-glucose (3) (1 mM final concentration) was combined with DTNB (1 mM final 
concentration) in 150 µL of 0.1 M phosphate buffer (pH 7). After incubating at 25 °C 
for 60 min, the reaction mixture was analyzed by LC-MS. The chromatogram showed 
three peaks (Fig A.3.7.a) with retention times 0.92, 8.07, and 9.41 min. Nothing was 
observed in the mass spectrum for the peak eluting at 0.92 min (Fig A.3.7.b) and so it 
was assigned as the solvent front. The 8.07 min peak, with identical retention time to 
pure cep-glucose (3), indeed only showed [3-H]- in the mass spectrum (Fig A.3.7.c). 








Figure A.3.7. LC-MS analysis of the mixture of cep-glucose (3) and Ellman’s 
reagent. a) Chromatogram showing three different peaks assigned as the solvent front 
(0.92 min), cep-glucose (3) (8.07 min), and Ellman’s reagent (DTNB) (9.41 min). b) 
Mass spectrum of the 0.92 min eluent, solvent front. c) Mass spectrum of the 8.07 
min eluent showing cep-glucose (3) d) Mass spectrum of the 9.41 min eluent showing 














[3 – H]- 












LC-MS analysis of cep-glucose in the presence of Ellman’s Reagent: 
 
Cep-glucose (3) (1 mM final concentration) was prepared in 150 µL 0.1 M phosphate 
buffer (pH 7.0) along with DTNB (1 mM final concentration). ESBL (1 U/ mL final 
concentration) was then added and the reaction mixture incubated at 25 °C for 1 h. To 
remove ESBL, the whole volume (150 µL) was purified through an Amicon Ultra 
centrifugal filter (regenerated cellulose, 3000 MWCO) in a benchtop centrifuge at 
14,000 RCF for 15 min. The filtrate was collected and analyzed by LC-MS.  
Analysis of the chromatogram (Fig A.3.8.a) shows that the peak corresponding to 
cep-glucose (3) (retention time = 8.07 min) has disappeared and a new peak with a 
retention time of 7.07 min has appeared. Analysis of the mass spectrum of the new 
7.07 min peak shows that it is comprised of two major species: the ring opened 
intermediate 4 (appearing as [4 – H]-, m/z 392.0115), and the mixed disulfide 
thioglucose-TNB (6) (appearing as [6 – H]-, m/z 543.1113) resulting from the 




that 4 arrives at the spectrometer slightly earlier than 6 (Figures A.3.8.b and A.3.8.c). 
Because it is in excess, unreacted DTNB is also observed in the chromatogram 
(retention time = 9.39 min) (Fig A.3.8.d). The other product of thioglucose 
elimination, 5, was not observed.  
 
Figure A.3.8. LC-MS analysis of the reaction of cep-glucose (3) and ESBL in the 
presence of Ellman’s reagent (DTNB). a) Chromatogram showing three peaks 
assigned as the solvent front (0.89 min), product mixture (7.07 min) and DTNB (9.39 
min). b)  Mass spectrum of eluent corresponding to the 7.07 min chromatogram peak, 
arriving at the mass spectrometer at 7.14 – 7.62 min. c) Mass spectrum of eluent 
corresponding to the 7.07 min chromatogram peak, arriving at the mass spectrometer 
at 7.45 – 8.35 min. d) Mass spectrum of eluent corresponding to 9.39 min peak. 
*Times recorded in the mass spectrum are higher than in the chromatogram due to the 
time it takes the eluent to travel from the HPLC to the spectrometer. 
 
 
(a) (b) 7.14 – 
7.62 min* 




[4 - H ]- 
Calculated Mass: 543.1113 
[6 - H]- 
Calculated Mass: 
392.0115 
[6 - H]- 
Calculated Mass: 
392.0115 
[4 - H]- 
Calculated Mass:  
543.1113 










Appendix IV. Stability of Cep-glucose in aqueous solution. 
The figures below detail performance of the Cep-glucose detection substrate 
alongside commercially purchased CENTA as they are kept in an aqueous 
preparation of 0.1 M phosphate buffer at +4°C for 1, 7, and 14 days post-preparation 
(Figs. A.4.1, A.4.2, A.4.3, respectively). Solutions are brought to r.t. and Ellman’s 
reagent (diluted to 250 μM final concentration from 100 mM stock prepared in 





















Appendix V. Thio-glucose calibration curve in the HRP-inhibition based 
electrochemical detection of Cep-glucose cleavage by ESBL (Fig. A.5.1). 
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